

PATENT COOPERATION TREATY

WO 00/15243
PCT/AU99/00775

PCT

From the INTERNATIONAL BUREAU

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

HUGHES, E., John, L.
Davies Collison Cave
1 Little Collins Street
Melbourne, VIC 3000
AUSTRALIE

TUESDAY 4 APR 2000

THURSDAY 13 APR 2000

Date of mailing (day/month/year) 23 March 2000 (23.03.00)		IMPORTANT NOTICE	
Applicant's or agent's file reference 2215689/EJH			
International application No. PCT/AU99/00775	International filing date (day/month/year) 15 September 1999 (15.09.99)	Priority date (day/month/year) 15 September 1998 (15.09.98)	
Applicant THE UNIVERSITY OF MELBOURNE et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU,CN,JP,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:
AE,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CR,CU,CZ,DE,DK,DM,EA,EE,EP,ES,FI,GB,GD,GE,
GH,GM,HR,HU,ID,IL,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,
PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,ZA,ZW
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 23 March 2000 (23.03.00) under No. WO 00/15243

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer J. Zahra Telephone No. (41-22) 338.83.38
--	---

PATENT COOPERATION TREATY

THURSDAY 27 APR 2000

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY



PCT

Pering

To: Agent :

DAVIES COLLISON CAVE
1 Little Collins Street
MELBOURNE VIC 3000

BRISBANE

NOTIFICATION OF RECEIPT OF DEMAND BY COMPETENT INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

(PCT Rule 59.3(e) and 61.1(b), first sentence
and Administrative Instructions, Section 601(a))

Date of mailing 26 APR 2000
(day/month/year) (26/4/00)

Applicant's or agent's file reference
2215689/ej

FRIDAY 28 APR 2000

IMPORTANT NOTIFICATION

International application No.
PCT/AU99/00775

International filing date (day/month/year)
15 SEP 1999 (15/9/99)

Priority date (day/month/year)
15 SEP 1998 (15/9/98)

Applicant

The University of Melbourne (et al.)

1. The applicant is hereby **notified** that this International Preliminary Examining Authority considers the following date as the date of receipt of the demand for international preliminary examination of the international application:

14 APR 2000 (14/4/00)

2. That date of receipt is:



the actual date of receipt of the demand by this Authority (Rule 61.1(b)).



the actual date of receipt of the demand on behalf of this Authority (Rule 59.3(e)).



the date on which this Authority has, in response to the Invitation to correct defects in the demand (Form PCT/IPEA/404), received the required corrections.

3. ☐ **Attention:** That date of receipt is **AFTER** the expiration of 19 months from the priority date. Consequently, the elections(s) made in the demand does (do) not have the effect of postponing the entry into the national phase until 30 months from the priority date (or later in some Offices) (Article 39(1)). Therefore, the acts for entry into the national phase must be performed within 20 months from the priority date (or later in some Offices) (Article 22). For details, see the *PCT Applicant's Guide, Volume II*.



(If applicable) This notification confirms the information given by telephone, facsimile transmission or in person on:

4. Only where paragraph 3 applies, a copy of this notification has been sent to the International Bureau.

Name and mailing address of the IPEA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail: pct@ipaaustralia.gov.au
Facsimile No. 02 6285 3929

Authorized officer


Telephone No.

MR SEAN MCLACHLAN
02 6283 2357

ATENT COOPERATION TREATY
PCT
INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2215689/ej	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).	
International application No. PCT/AU 99/00775	International filing date (<i>day/month/year</i>) 15 September 1999	Priority Date (<i>day/month/year</i>) 15 September 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl.⁷ A61K 38/08; C07K 2/00, 14/705; C12N 15/12		
Applicant 1. THE UNIVERSITY OF MELBOURNE et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	This REPORT consists of a total of 4 sheets, including this cover sheet. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of sheet(s).																								
3. This report contains indications relating to the following items: <table style="width: 100%; margin-top: 10px;"> <tr> <td style="width: 5%;">I</td> <td style="width: 5%; text-align: center;"><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td style="text-align: center;"><input type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>		I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 14 April 2000	Date of completion of the report 14 December 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  ARATI SARDANA Telephone No. (02) 6283 2627

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of .
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages , received on with the letter of .
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of .
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of .

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 1-9, 11 and 12	YES
	Claims 10 and 13-15	NO
Inventive step (IS)	Claims 1-9, 11 and 12	YES
	Claims 10 and 13-15	NO
Industrial applicability (IA)	Claims 1-15	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

NOVELTY (N): Claims 10 and 13-15

Current application refers to a method of treating diseases of airway epithelium by activating protease activated receptors (PARs) which mediate inhibition of bronchoconstriction and/or inflammation.

Document 1 (D1) : Nature, vol. 398, (11 March 1999), Pages 156-60, (Cocks TM et al.)
 "A perspective role for protease-activated receptors in the airways"

Because D1 was published between the claimed priority date and the International filing date of the present application, it is not considered prior art for the purpose of Article 33(2) and (3) of the PCT.

Document 2 (D2) : Biochem J, vol. 314 (Pt 3), (15 March 1996) Pages 1009-16, (Bohm SK et al.)
 "Molecular cloning, expression and potential functions of the human proteinase - activated receptor -2"

D2 discloses expression of recombinant PAR2. Claims 13, 14 and 15, directed to an isolated or recombinant molecule of PAR lack novelty in view of the above disclosure.

Document 3 (D3) : Journal of Neurochemistry, vol. 69 (5), (1997), Pages 1890-1896, (Smith-Swintosky VL et al.)
 "Protease-Activated Receptor-2 (PAR 2) is present in the Rat Hippocampus and is associated with Neurodegeneration."

D3 discloses the following activators of PAR

- (a) trypsin
- (b) hesapeptide SLIGRL and
- (c) hexapeptide SF LLRN

Claim 10, directed to a composition comprising activators of PAR, lacks novelty in view of the above disclosure.

Continued in Supplemental Box

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of : V2

Document 4 (D4) : Biochemical and Biophysical Research Communications, vol. 241 (3), (1997), Pages 762-764, (Bono F. et al)
"Induction of Vascular Smooth Muscle Cell Growth by Selective Activation of the Proteinase Activated Receptor-2 (PAR-2)

D4 discloses trypsin and a hexapeptide SLIGKV as activators of PAR-2. This disclosure deprives claim 10 of its novelty.

Document 5 (D5) : WO 98/18456 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 7 May 1998

D5 is directed to a recombinant protease activated receptor 3. This disclosure deprives claim 13 (directed to an isolated molecule of PAR) of its novelty.

Document 6 (D6) : WO 99/43809 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 2 September 1999

D6 is directed to a recombinantly expressed protease-activated receptor 4. This disclosure deprives claim 13 of its novelty.

Therefore claims 10 and 13-15 are not novel.

The Attorney's arguments that PAR molecules being claimed are novel because these molecules have new features of being

- (1) isolatable from airway epithelium and
- (2) confer inhibition of bronchoconstriction and/or inflammation of airway epithelium upon activation are not persuasive.

Airway epithelium is morphologically similar to upper intestinal epithelium and also expresses PAR2. Isolating PARS from another source (morphologically similar) does not render the known molecules novel. The inhibition of bronchoconstriction and/or inflammation of airway epithelium upon activation is identification of a new property of known PAR molecules.

Therefore claims 10 and 13-15 are still not novel and do not involve an inventive step.

INVENTIVE STEP (IS): Claims 10 and 13-15

As for novelty

INDUSTRIAL APPLICABILITY (IA)

Claims 1-9 are to method of treatment are subject to Rule 67.1 and as such do not require an International Preliminary Examination. However, as they do not contravene Australian law, they have been examined

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2215689/EJH/AF	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/AU 99/00775	International filing date (<i>day/month/year</i>) 15 September 1999	(Earliest) Priority Date (<i>day/month/year</i>) 15 September 1998
Applicant 1. THE UNIVERSITY OF MELBOURNE et al.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of **4** sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international application, the international search was carried out on the basis of the sequence listing:

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (See Box II).

4. With regard to the **title**, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**, ☒ the text is approved as submitted by the applicant

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ None of the figures

☐ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: A61K 38/08; C07K 2/00. 14/705; C12N 15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

FILE WPAT AND CAPLUS KEYWORDS IN ELECTRONIC DATABASE BOX BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
DERWENT, CHEMICAL ABSTRACTS. KEYWORDS: PROTEASE ACTIVATED RECEPTOR OR PAR**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	Nature, vol. 398, (11 March 1999), Pages 156-60, (Cocks TM et al.) "A protective role for protease- activated receptors in the airways" See whole document	1-15
X	Biochem J, vol. 314 (Pt 3), (15 March 1996) Pages 1009-16, (Bohm SK et al.) "Molecular cloning, expression and potential functions of the human proteinase - activated receptor - 2" See whole document	13, 14 and 15
X	Journal of Neurochemistry, vol. 69 (5), (1997), Pages 1890-1896, (Smith - Swintosky VL et al.) "Protease-Activated Receptor-2 (PAR 2) is present in the Rat Hippocampus and is associated with Neurodegeneration". See whole document	10

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" Document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
09 November 1999Date of mailing of the international search report
22 NOV 1999Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606 AUSTRALIA
E-mail address: pct@ipaustalia.gov.au
Facsimile No.: (02) 6285 3929Authorized officer

ARATI SARDANA
Telephone No.: (02) 6283 2627

C (Co) uation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Biochemical and Biophysical Research Communications, vol 241 (3), (1997), Pages 762-764, (Bono F et al.) "Induction of Vascular Smooth Muscle Cell Growth by Selective Activation of the Proteinase Activated Receptor-2 (PAR-2)". See whole document	10
X	WO 98/18456 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 7 May 1998. See whole document	13
X	WO 99/43809 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 2 September 1999 See whole document	13

Information on patent families members

PCT/AU 99/00775

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
WO	98/18456	EP	948323	US	5892014



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/08, C07K 2/00, 14/705, C12N 15/12		A1	(11) International Publication Number: WO 00/15243
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/AU99/00775		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 September 1999 (15.09.99)			
(30) Priority Data: PP 5922 15 September 1998 (15.09.98) AU PP 8658 12 February 1999 (12.02.99) AU			
(71) Applicant (for all designated States except US): THE UNIVERSITY OF MELBOURNE [AU/AU]; Grattan Street, Parkville, VIC 3052 (AU).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): COCKS, Thomas, Mathew [AU/AU]; 11 Park Street, Abbotsford, VIC 3067 (AU). MOFFATT, James, David [AU/AU]; 299A Rae Street, North Fitzroy, VIC 3068 (AU).		With international search report.	
(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).			
(54) Title: A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME			
(57) Abstract			
<p>The present invention relates generally to a method of inducing, stimulating or otherwise facilitating bronchoprotection in humans and animals by modulating bronchial constriction and/or inflammation. The present invention is predicated in part on the identification of receptors in airway epithelium which mediate inhibition of bronchoconstriction and/or inflammation following their activation. More particularly, the present invention identifies that activation of protease activated receptors (PARs) results in relaxation of airway epithelium. Activation of airway epithelium PARs inhibits bronchoconstriction and/or inflammation and thereby mediates bronchoprotection of the airways. The present invention further provides a method for the prophylaxis and treatment of disease conditions in airways such as asthma and bronchitis and further provides methods for the diagnosis and screening of agents useful in the prophylaxis and treatment of airway disease conditions.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME

The present invention relates generally to a method of inducing, stimulating or otherwise facilitating bronchoprotection in humans and animals by modulating —
5 bronchial constriction and/or inflammation. The present invention is predicated in part on the identification of receptors in airway epithelium which mediate inhibition of bronchoconstriction and/or inflammation following their activation. More particularly, the present invention identifies that activation of protease activated receptors (PARs) results in relaxation of airway epithelium. Activation of airway
10 epithelium PARs inhibits bronchoconstriction and/or inflammation and thereby mediates bronchoprotection of the airways. The present invention further provides a method for the prophylaxis and treatment of disease conditions in airways such as asthma and bronchitis and further provides methods for the diagnosis and screening of agents useful in the prophylaxis and treatment of airway disease
15 conditions.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers
20 but not the exclusion of any other element or integer or group of elements or integers.

Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

25

The subject specification contains amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length,
30 type of sequence (e.g. protein (PRT), etc) and source organism for each amino acid

- 2 -

sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (eg. <400>1, <400>2, etc).

5

Many receptors for biologically-active effector molecules are large proteins embedded in biological membranes. They serve as transducers of information mediated by effectors such as hormones and cytokines, and are also important in the mechanism of action of pharmaceutical agents. For example, receptors located within the outer regions of the cellular membrane act to transduce such information into the cell, which may then respond in a number of different ways *via* specific secondary messenger systems. Therefore, these types of receptors have specific extracellular and intracellular domains which allow information, such as hormonal signals, to be appropriately detected and processed by cells.

15

Protease-activated receptors (PARs) are a relatively new subtype of a superfamily of membrane receptors which have seven membrane-spanning regions and are coupled to intracellular second messenger mechanisms *via* G proteins. The three known members, respectively designated PAR1, PAR2 and PAR3, have been cloned, and shown to be expressed in vascularised tissues comprising endothelial and smooth muscle cells (PAR1 and PAR2) and platelets (PAR1 and PAR3). A fourth receptor, designated PAR4, has also recently been demonstrated on platelets of PAR3 deficient mice and has been cloned (Kahn *et al*, 1998); the human homologue has also been cloned (Xu *et al*, 1998).

25

PARs are activated in a unique manner, which is illustrated in Figure 1. As the name indicates, limited proteolysis by specific proteases (proteinases) removes part of the extracellular N-terminal region of the receptor, so that the newly-shortened N-terminal acts as a ligand for an as yet undefined binding region on the remainder of the receptor in order to signal the cell to respond. Thus, PARs have their own inbuilt or "tethered" ligands, and the specific protease activity reveals that these

30

- 3 -

latent, intrinsic ligands act as ligands in their own right rather than as exogenous effectors.

PAR1 (Vu *et al*, 1991; Coughlin *et al*, 1992) and PAR3 (Ishihara *et al*, 1996) are
5 activated primarily by the blood-borne protease, thrombin, which is believed to be involved in thrombosis, inflammation and mitogenic growth (De Caterina & Sicari, 1993; Dennington & Berndt, 1994; Fager, 1995). For example, thrombin causes smooth muscle in the airways to proliferate, which may cause the airway to thicken and become obstructed. PAR1 is also located on vascular endothelial cells, where,
10 like many other receptor types, stimulation leads to release of nitric oxide (NO) and other factors which then cause the muscle in the wall of the vessels to relax (Muramatsu *et al*, 1991; Tesfamariam *et al*, 1993; Tesfamariam, 1994; Hwa *et al*, 1996; Saifeddine *et al*, 1996). Under normal circumstances, the enzymatic activity of thrombin is strongly suppressed by a number of endogenous inhibitors.

15

PAR2 differs from both PAR1 and PAR3 receptors in that it is activated not by thrombin, but by trypsin and trypsin-like enzymes, such as mast cell-derived tryptase (Molino *et al*, 1997). Trypsin is usually confined to the upper gastrointestinal tract after its generation by activation of its pancreatic precursor,
20 trypsinogen. Trypsinogen is induced in vascular endothelial cells by tissue plasminogen activator [TPA] (Koshikawa *et al*, 1997). Tryptase is released in large concentrations from mast cells (Caughey, 1994). Mast cells are believed to have a central role in the pathogenic manifestations of asthma. Tryptase stimulates mucus release and can inactivate some peptides such as vasoactive intestinal peptide
25 (VIP) that relax airway smooth muscle in experimental animals. This suggests that the PARs play a role in the aetiology of airway disease by inducing contraction of smooth muscle cells.

In addition to tryptase, tryptase-like enzymes are released by clara cells (Yasuoka
30 *et al*, 1997), which are common in the epithelium lining the small bronchi of most mammals, including humans, the trachea of the mouse, and by lymphocytes which

enter the inflamed airway in large numbers. Trypsin has been localised to normal airway epithelium (Koshikawa *et al*, 1997). In addition, tryptase-like enzymes are thought to be involved in a number of inflammatory responses and diseases, such as atherosclerosis (Atkinson *et al*, 1994; Kovanen *et al*, 1995) and varicosis
5 (Yamada *et al*, 1996). Furthermore and importantly, as well as directly activating mast cell degranulation *via* IgE-antigen recognition, the antigens of some dust mites and pollens are proteases with trypsin-like activity (Caughey, 1997). Therefore, allergens which are central to, and the causal agents of, many airway diseases have the potential to directly and indirectly activate PAR2.

10

PAR1 and PAR2, but not PAR3 (Isihara *et al*, 1997) can also be activated by short synthetic peptide sequences corresponding to those of the tethered ligands. For PAR1, this tethered ligand is SFLLRN-NH₂ (single amino acid code [<400>1], which is also known as TRAP (thrombin receptor-activating peptide)). The tethered ligand
15 sequence for mouse PAR2 is SLIGRL-NH₂ [<400>2], and is referred to herein as PAR2 activating peptide (PAR2-AP). Therefore, these peptides can be used to mimic enzyme mediated PAR activation and to study the effects of PAR activation.

The genes for PAR1, PAR2 and PAR3 have been cloned (Vu *et al*, 1991; Nystedt
20 *et al*, 1994; Bohm *et al*, 1996a; Saifeddine *et al*, 1996 and Ishihara *et al*, 1997).

PAR2 mRNA has been shown to be highly expressed in vascularised or endothelialised tissues such as the stomach, intestine, pancreas, kidney and liver. In the gut, PAR2 mRNA is located mainly in epithelial cells (Bohm *et al*, 1996b). In blood vessels, functional PAR2 has been localised nearly exclusively to endothelial
25 cells, where, like PAR1, it mediates endothelium-dependent vasodilation (Hwa *et al*, 1996; Saifeddine *et al*, 1996). It has been proposed that PAR2 acts as a trypsin sensor in the pancreas (Bohm *et al*, 1996a) and is involved in a possible cytoprotective mechanism for gut epithelia exposed to trypsin (Bohm *et al*, 1996b). Apart from these proposed activities, little is known of other physiological roles for
30 these receptors.

- 5 -

Following activation, PARs are inactivated by rapid internalisation, which also provides the signals for rapid generation of new receptors from intracellular pools and *de novo* protein synthesis (Hoxie *et al*, 1993; Bohm *et al*, 1996b). This provides a powerful self-replenishing system to maintain adequate tissue levels of
5 the receptors.

Like PAR1, PAR2 mediates relaxation of arteries *via* the release of nitric oxide (NO; Moncada *et al*, 1991) and of endothelium-derived hyperpolarising factor (EDHF: Garland *et al*, 1995), although the EDHF-dependent mechanism for PAR1 is
10 different from that for PAR2. The mechanisms of receptor recycling also regulate the way in which endothelial cells recover their ability to respond to further protease challenge, at least within two to three hours after the first challenge. For PAR1, this recovery process involves rapid recycling of receptors (30 min- 150 min) without the tethered ligand sequence, but no new N-terminal receptors are produced. For
15 PAR2, however, fully intact new receptors are rapidly synthesised from stable mRNA, and are inserted into the plasma membrane (Bohm *et al*, 1996a).

Only PAR1 has been identified in the human vasculature (Nelken, 1992), where expression was reported to be isolated to endothelial cells in atheroma-free
20 arteries. In vessels affected by atherosclerosis, PAR1 mRNA was found in endothelial, smooth muscle and mesenchymal-appearing cells. Studies on human endothelial cell PAR function have been limited to the measurement of calcium fluxes in transfected cell lines (Mari, 1995) and umbilical vein endothelial cells (Ngaiza *et al*, 1991; Kruse *et al*, 1995). An atypical PAR has also been identified in
25 human coronary arteries (Hamilton *et al*, 1998).

The incidence and prevalence of airway diseases such as asthma and bronchitis, which are characterised by airflow obstruction, inflammation and pathological changes in airway tissue are increasing globally (Barnes *et al*, 1996a). However, it
30 is unknown why some people develop these types of airway diseases, while other people exposed to the same environmental factors do not. One possibility is that

- 6 -

the airway defences of patients who develop the disease are less efficient than those of non-afflicted subjects.

Asthmatic patients suffer from episodic airflow limitation caused by bronchospasm, oedema and thickening of the airway walls. In addition, one of the hallmarks of asthma is that the bronchi are hypersensitive to specific and non-specific stimuli, causing them to contract too much and too sensitively, thereby narrowing the airways and making breathing difficult (Barnes, 1996b; Barnes *et al*, 1996c). The most widely-used treatment for asthma is administration of drugs that cause the bronchial muscles to relax and the airways to dilate, thus restoring the ability to breath. The most commonly used drugs for this purpose are the so-called beta-2 agonists. These drugs stimulate another subtype of the seven transmembrane, G protein-coupled receptor superfamily, the beta-2 adrenoceptors, which are located on the muscle and mediate relaxation *via* well-defined biochemical mechanisms. While beta-2 agonists are effective in most patients, it has recently been discovered that some asthmatics respond poorly to beta-2 agonists, and the agonists may mediate down-regulation of patient responses during chronic treatment due to genetic mutations in the beta-2 adrenoceptor sequence. Additionally, concerns have been raised about the possibility that regular use of beta 2-adrenoceptor agonists may increase the risk of death from asthma.

Airway disease like asthma and bronchitis are predicted to continue their dramatic rate of increase in developed societies, and therefore, new therapies, procedures and methods of diagnosis, and methods of screening for prophylactic or therapeutic agents are urgently needed.

In work leading up to the present invention, the inventors identified that activation of PARs located immunohistochemically on airway epithelium, caused dilation of bronchi and bronchioles. This physiologically relevant protective response in airways was mediated mainly by a cyclooxygenase product (eg. PGE₂) released from the epithelium. In addition, after receptor desensitisation due to internalisation

- 7 -

and degradation, functional PARs are rapidly replenished to the cell surface by protein trafficking and *de novo* synthesis. In accordance with the present invention, epithelial PARs, and in particular PAR2 are regarded as potential targets for the development of new therapies for inflammatory diseases like asthma and
5 bronchitis.

The inventors have now surprisingly found that PAR2 in the epithelial layer has an anti-inflammatory role in the airways, and that PAR2 epithelial and smooth muscle cells are differentially regulated.

10

The inventors have shown that epithelial PARs and in particular PAR2, initiate important autocrine and paracrine protective tissue responses in the airways which include regulation of smooth muscle contractility, inflammatory cell migration and function, neural activity and tissue remodelling, and therefore enable new therapies
15 for airway inflammatory diseases like asthma and bronchitis.

The present invention is predicated in part on the identification of airway epithelial PARs which modulate bronchodilation and inflammation. More particularly, the inventors have identified PARs in airway epithelium which, upon activation,
20 simulate, induce or otherwise facilitate inhibition of bronchoconstriction and/or inflammation in humans and animals.

Accordingly, one aspect of the present invention provides an isolated molecule comprising PAR activity wherein said molecule is isolatable from airway epithelium
25 and upon activation, stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in humans and animals.

Reference herein to animals includes apart from humans, primates, livestock animals (e.g. sheep, cows, horses, pigs, goats), laboratory test animals (e.g. mice,
30 rats, rabbits, guinea pigs), companion animals (eg. cats, dogs) and captive wild animals (e.g. foxes, deer, kangaroos).

- 8 -

Although the present invention extends to any PAR expressed in airway epithelium, it is particularly directed to PAR1 and PAR2 and is most particularly directed to PAR2. Accordingly, reference hereinafter to "PAR2" includes other PARs which behave in a functionally similar manner.

5

Another aspect of the present invention is directed to an isolated molecule comprising PAR2 activity wherein said molecule is isolatable from airway epithelium and upon activation, stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in humans and animals.

10

Preferably, the PAR2 is in isolated form meaning that it has undergone at least one purification step away from contaminating material. However, PAR2 may also be part of a membrane formulation or preparation. PAR2 may also be prepared in recombinant form or be chemically synthesized.

15

The recombinant form of PAR2 may be as a single polypeptide or a modular molecule comprising various parts of PAR2 or its homologues.

20

According to this aspect of the present invention there is provided a polypeptide in recombinant form which is homologous to a PAR2 in airway epithelium, said polypeptide comprising an N-terminal portion, transmembrane portion, an intracellular portion and a ligand binding portion wherein upon proteolytic cleavage of the N-terminal portion, the remaining extracellular portion folds onto or otherwise interacts with the ligand binding portion to activate the recombinant polypeptide.

25

Each portion of the above polypeptide may be derived from airway epithelium PAR2 or it may be in modular form meaning that the portions are derived from different molecules. For example, the extracellular portion may be from PAR2, the transmembrane portion may be from another receptor and the intracellular portion

30 may be any G-protein interacting region.

- 9 -

Yet another aspect of the present invention provides a recombinant, synthetic or purified, naturally occurring molecule comprising PAR2 activity wherein said molecule is isolatable from airway epithelium and, upon activation by a PAR2 activating peptide, stimulates, induces or otherwise facilitates inhibition of
5 bronchoconstriction and/or inflammation in humans and animals.

The identification of PAR2 in airway epithelium provides a mechanism for treating airway disease conditions which result in bronchoconstriction and/or inflammation of airway tissue.

10

In a preferred embodiment, the condition to be treated is a broncho-constrictive disease such as but not limited to asthma, bronchitis including bronchiolitis obliterans, rhinitis, hayfever, alveolitis of diverse aetiologies, ciliary dyskinesin sarcoidosis and pulmonary inflammatory diseases. Diseases involving PAR are
15 summarized in Table 1 below:

TABLE 1
Diseases involving PAR

(A) Diseases of the lung and airways, including but not limited to:

- 5
- Alveolitis of diverse aetiologies
 - Asthma
 - Bronchitis
 - Bronchiolitis, including bronchiolitis obliterans
 - 10 ● Ciliary dyskinesia
 - Pulmonary fibrosis of diverse aetiologies
 - Pulmonary hypertension and its sequelae
 - Sarcoidosis
- 15 Proposed galenical forms: aerosols of solutions, suspensions or dry powders, including micronised preparations; nasal sprays; liposomal formulations, including cationic liposomes for gene vector transfer.

(B) Diseases of the gastrointestinal tract, including but not limited to:

- 20
- Crohn's disease
 - Gastric and gastrointestinal ulceration, including ulceration triggered by NSAID therapy
 - Inflammatory bowel disease
 - 25 ● Intestinal adhesion induced by surgery, injury or other mechanisms
 - Ulcerative colitis
 - Hirschsprung's disease
 - Irritable Bowel Syndrome
- 30 Proposed galenical forms: oral formulations, including encapsulated, enteric-coated and sustained release matrix formulations; suppositories; enemas; implantable gels

or slow release matrixes.

(C) Disease of the eye, including but not limited to:

- 5 • Conjunctival inflammation
 - Corneal neovascularisation
 - Corneal ulceration
 - Glaucoma
- 10 Proposed galenical forms: drops and gels, including slow release implantable matrixes; additions to contact lenses as coatings or integral matrix component.

(D) Disease of the genitourinary tract, including but not limited to:

- 15 • Ciliary dyskinesia
- Cystitis
- Disorders of the fallopian tubes, including infertility
- Incontinence
- Pelvic inflammatory disease
- 20 • Regulation of the contractility of the uterus in pregnancy
- Urethral inflammation

(E) Disease of the auditory canal and middle ear, including but not limited to:

- 25 • ciliary dyskinesia
- Eustachian canal obstruction
- Otitis media

- Proposed galenical forms: drops and gels, including slow release implantable
- 30 matrixes; additions to grommets and stents as coatings or integral matrix component.

(F) Diseases of the vasculature and lymphatics, including but not limited to:

- atherosclerosis
- ischaemia
- 5 • lymphoedema
- modulation of angiogenesis
- systemic, pulmonary and portal hypertension
- re-anastomosis
- thrombosis
- 10 • vascular reperfusion injury

Proposed galenical forms: injectables; drops; gels including slow release
implantable matrices; wrappings; additions to surgical devices including stents,
grommets, valves, electrodes, catheters, synthetic vessels, as coatings or integral
15 matrix component.

- 13 -

According to this aspect of the present invention, there is contemplated a method for the prophylaxis or treatment of an airway disease condition in a human or animal said method comprising administering to said human or animal an effective amount of an agent capable of activating an airway epithelium PAR for a time and
5 under conditions sufficient for activation of said PAR to occur wherein the activated PAR stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation.

Preferably, the PAR is PAR2.

10

According to this preferred embodiment, there is provided a method for the prophylaxis or treatment of an airway disease condition in a human or animal said method comprising administering to said human or animal an effective amount of an agent capable of activating an airway epithelium PAR2 for a time and under
15 conditions sufficient for activation of said PAR2 which then stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation.

The agent may be a nucleotide sequence, low molecular weight compound, or a derivative, part, fragment, analogue, mimetic, mimotope or chemical equivalent of
20 all or a portion of PAR2. In particular, the agent may be a peptide having similar biological activity to SFLLRN-NH₂ [<400>1] and/or SLIGRL-NH₂ [<400>2] and/or SLIGKV-NH₂ [<400>3] (see Blackhart *et al*, 1996). Gene therapy may also be employed such as using cationic liposomes for gene vector transfer.

25 The compositions may be administered orally, intranasally, *via* aerosol, *via* inhalation, parenterally, intramuscularly, intreperitoneally, intravenously, rectally or subcutaneously amongst other routes. Administration may also be facilitated by fusing the agent to a membrane penetrating molecule such as penetration or the TAT protein from HIV-1 (see Schwarze *et al*, 1999). Gene transfer vectors may
30 also be employed.

- 14 -

Accordingly, another aspect of the present invention is directed to a composition useful for facilitating bronchoprotection said composition comprising an activator of PARs in airway epithelium and one or more pharmaceutically acceptable carriers and/or diluents.

5

The activator of this aspect of the present invention may be referred to as an "active ingredient" or "agent". The activator may also be considered as an "agonist" of PAR activation.

- 10 Compositions suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. They are generally stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or
- 15 dispersion medium containing, for example, water, ethanol, polyoil (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and
- 20 the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients
- 25 enumerated above, as required, followed by, for example, filter sterilization or sterilization by other appropriate means. In the case of sterile powders for the preparation of sterile injectable solutions, a preferred method of preparation includes vacuum drying and freeze-drying which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered
- 30 solution.

- 15 -

When the active ingredient is suitably protected, it may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets.

5 The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: a binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; and a lubricant such as magnesium stearate. Any material used in preparing any dosage unit form should be pharmaceutically pure
10 and substantially non-toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents,
15 dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients
20 can also be incorporated into the compositions.

Effective amounts of the subject agent will vary depending on the condition to be treated by may range from 0.001 ng/kg body weight to 100 mg/kg body weight. The agent may be administered every minute or hourly, daily, weekly or monthly.
25 The agent may be used prophylactically or in the treatment of a disease condition.

Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton,
30 Pennsylvania, USA.

- 16 -

Another aspect of the present invention relates to a method of diagnosis of a condition mediated by bronchial contraction, comprising the step of activating a PAR as described above and measuring cellular response(s). The types of response(s) induced can be used as an indicator of pre-disposition to one or more
5 of the conditions described above, thereby enabling diagnosis.

This method also enables the screening of putative therapeutic or prophylactic agents for one or more of these conditions. Accordingly, another aspect of the present invention provides a method of screening putative agents for the treatment
10 or prophylaxis of a direct or indirect condition mediated by changes in smooth muscle cell contractility, comprising the step of exposing a PAR to the putative agent and measuring the ability of the agent to activate the PAR. Preferably, the PAR is PAR1 or PAR2 or a PAR-like receptor.

15 The present invention further extends to antibodies to PAR2 and in particular to extracellular portions of PAR2. Such antibodies may be monoclonal or polyclonal. The antibodies of the present invention are particularly useful as therapeutic (e.g. as agonists) or as diagnostic agents.

20 PAR2 of the present invention may be used, for example, as an antigen to screen for naturally occurring antibodies to PAR2 in humans or animals. Alternatively, specific antibodies to PAR2 may be used to screen for PAR2 or an antigenic derivative or relative in a sample. This may provide an indication of whether PAR2 is immunologically normal and, if not, this may indicate a propensity to develop
25 airway disease. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA.

Accordingly, the present invention provides a method for detecting the presence of a PAR2 or an antigenic fragment thereof in a biological sample, said method
30 comprising contacting said biological sample with an antibody to said PAR2 for a time and under conditions sufficient for a complex to form between said PAR2 and

- 17 -

an antibody and then detecting said complex.

- A biological sample according to this aspect is one which potentially contains PAR2 containing cells such as flem, respiratory mucus or biopsy tissue. In this context, a
- 5 biological sample includes tissue and tissue extract. The presence of PAR2 in a biological sample may be determined using a wide range of immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. This includes both single-site and two-site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays.
- 10 Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay techniques exist, and all are intended to be encompassed by the present invention.
- 15 Reference herein to "PAR" and more particularly "PAR2" includes all derivatives, mutants, parts, fragments, portions, homologues, mimetics, mimotopes, analogues or chemical equivalents of all or part of PAR2.

- Analogues and mimetics include molecules which contain non-naturally occurring
- 20 amino acids as well as molecules which do not contain amino acids but nevertheless behave functionally the same as PAR2. Natural product screening is one useful strategy for identifying analogues and mimetics. Natural product screening involves screening environments such as bacteria, plants, animals, rainforests, riverbeds, seabeds, aquatic environments, coral and antarctic or arctic
- 25 environments for naturally occurring molecules which mimic, agonise or antagonise the subject of the present invention. Analogues of the subject PAR2 contemplated herein include modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptide molecule or
- 30 their analogues.

- 18 -

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; 5 trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

- 10 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

- The carboxyl group may be modified by carbodimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
- 15

- Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; 20 formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

25

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

30

Modification of the imidazole ring of a histidine residue may be accomplished by

- 19 -

alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 2.

TABLE 2

	Non-conventional	Code	Non-conventional	Code
5	amino acid		amino acid	
	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate		Mgabul-N-methylarginine	Nmarg
	aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
10	carboxylate		L-N-methylaspartic acid	Nmasp
	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
	carboxylate		L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
15	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
20	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
25	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
30	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
	D-threonine	Dthr	L-norleucine	Nle

	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
5	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
10	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methyllleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methylllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
15	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
20	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
25	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
30	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis

	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
5	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
10	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
15	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
20	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
25	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 23 -

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and

10 hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α-methylamino acids, introduction of double bonds between C_α and C_β atoms of

15 amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

All these types of modifications may be important to stabilise PAR2 or a PAR2

20 modulating agent. This may be important if these molecules are used, for example, in the manufacture of a therapeutic or diagnostic composition.

The present invention further contemplates chemical equivalents of the subject polypeptides. Chemical equivalents may not necessarily be derived from the

25 subject PAR2 itself but may share certain conformational or functional similarities. Alternatively, chemical equivalents may be specifically designed to mimic certain physiochemical properties of the polypeptides. Chemical equivalents may be chemically synthesised or may be detected following, for example, natural product screening.

30

Reference herein to the PAR2 of the present invention should be read as including

reference to all forms of the PAR2 including, by way of example, isoforms, monomeric, dimeric and multimeric forms and peptide fragments PAR2 as well as other PARs.

- 5 The invention will now be described in detail by way of reference only, to the following non-limiting Examples and Figures, in which:

Figure 1 is a schematic representation of the PAR2 receptor. The black loops depict the membrane-spanning regions in a theoretical cell. The receptor is
10 activated by trypsin (or by other trypsin-like proteases, eg tryptase) by cleavage of the arginine³⁴-serine³⁵ peptide bond amino-terminally to the arginine³⁴ in the extracellular N-terminal domain. The next approximately six amino acids of the new N-terminal (called the tethered ligand sequence, solid box) now 'flip' on to another, undefined region of the remaining receptor to initiate intracellular G-
15 protein (G) coupling and signalling, shown here as "responses". The putative tethered ligand binding region ("R") of the receptor can also be directly activated by exogenous addition of a synthetic peptide identical or homologues to the tethered ligand sequence SLIGRL-NH₂ (single letter amino acid code) designating the mouse PAR2 activating sequence. The similar but genetically distinct PAR1, or
20 thrombin receptor, is enzymically activated by thrombin by cleaving a arginine⁴¹-serine⁴²-bond and the synthetic tethered ligand sequence SFLLRN-NH₂ designating the human PAR2 activating sequence.

Figure 2 is a chart recording showing changes in isometric force in a ring of mouse
25 bronchus contracted to approximately 70% maximal force (F_{max}) with carbachol. The characteristic spontaneous fluctuations in active force fell markedly, then recovered at two points. After the second fall and recovery, extra carbachol was added to increase the level of active force above 70% F_{max} . A high, single concentration of the PAR2 activating peptide, PAR2-AP, (SLIGRL-NH₂) then
30 induced a large relaxation.

- 25 -

Figure 3 shows the effect of increasing concentrations of nifedipine (-logM) on spontaneous and contractile agonist-induced phasic contractile activity in isolated ring segments of human large coronary artery. The figures shows four rings of coronary artery stretched, twice (arrows) to 5g resting force, then contracted with 5 cumulatively increasing concentrations of the thromboxane A₂ mimetic, U46619 (-logM).

Figure 4 is a chart recording showing changes in isometric force in a ring of mouse bronchus contracted to 40%-50% F_{max} with carbachol, and the effects of the PAR2 activating peptide, PAR2-AP (SLIGRL-NH₂) and trypsin in the absence and 10 presence of nifedipine (0.3μM).

Figure 5 shows the effect of removal of the epithelium on relaxation to the PAR2 activating peptide, PAR2-AP (SLIGRL-NH₂) in rings of the guinea-pig isolated 15 bronchus. (A) Chart recordings of changes in isometric force in two rings contracted to 60%-70% F_{max} with carbachol (-logM) after which PAR2-AP was added (-logM). (B) Group data from six experiments described in (A). Responses are expressed as percentages of the contraction to carbachol and values are mean ±SEM. Positive values represent contractions.

20

Figure 6 is a chart recording demonstrating the obligatory role of the epithelium in mediating relaxation to the PAR2 activating peptide, PAR2-AP (SLIGRL-NH₂, --logM), in isolated spiral strip preparations of the guinea-pig bronchus. Strips were contracted to approximately 25% F_{max} with carbachol.

25

- 26 -

Figure 7 shows chart recordings depicting both the technique used to record relaxation in isolated mouse bronchial ring preparations, and the efficacy of the PAR2 activating peptide, PAR2-A P (SLIGRL-NH₂) and thrombin receptor activating peptide, TRAP (SFLLRN-NH₂) as broncho-relaxant agents. The time calibration bar represents 40 min, 12 min and 4 min during the F_{max} contraction, the 40% F_{max} contraction with carbachol and the additions of both peptides, respectively.

Figure 8 depicts the sensitivity and maximum relaxation to (A) SLIGRL- NH₂ (PAR2-AP), (B) SFLLRN-NH₂ (TRAP), (C) trypsin and (D) thrombin in isolated mouse bronchial rings with epithelium and the effect of potential inhibitors of these responses. All responses are expressed as percentage relaxation of the initial levels of active force induced by carbachol (30%-60% F_{max}). Values are mean ±SEM from 6-9 experiments and positive values represent contractions. Drugs used were L-NOARG (100μM), a nitric oxide (NO) synthase inhibitor; HbO, (oxyhaemoglobin, 20μM), a NO scavenger, and Indo (indomethacin, 3μM) or aspirin (100μM), both of which are cyclooxygenase inhibitors which prevent the synthesis of prostaglandin.

Figure 9 shows the effect of desensitisation to trypsin (post-trypsin) and thrombin (post-thrombin) on the relaxation to PAR2-AP in ring preparations of isolated mouse bronchi. All responses are expressed as percentage relaxation of the initial levels of active force induced by carbachol (30%-60% F_{max}). Values represent mean ±SEM from 5 experiments.

- 27 -

Figure 10 depicts the sensitivity and maximum relaxation to authentic prostaglandin E_2 (PGE_2), a stable analogue of PGE_2 , PGE_2 ethanolamide and a stable analogue of prostacyclin (PGI_2), carbaprostacyclin, in ring preparations of mouse isolated bronchi. Values are mean \pm SEM from the number of experiments (n) shown in parentheses, and are expressed as percentage relaxation of the initial level of active force induced by carbachol (30-60% F_{max}).

Figure 11a shows the near-complete and rapid recovery of PAR2-mediated relaxation to trypsin following desensitization to trypsin (\emptyset i.e. "zero") in ring preparations of isolated mouse bronchi. This recovery (30 minutes) was abolished by the protein trafficking inhibitor, brefeldin A ($10\mu M$). All responses are expressed as percentage relaxations of the initial levels of active force induced by carbachol (30-60% F_{max}). Values are mean \pm SEM from the number of experiments (n) shown in parentheses.

15

Figure 11b shows results of a second experiment demonstrating that epithelial PAR2 receptors in mouse bronchi are regulated by a rapid turnover following desensitisation to trypsin. (a) Responsiveness to trypsin (0.3 U/ml) recovered to approximately 70% of control at 45 minutes from the zero recovery time (the time at which trypsin caused no response after the desensitising concentration of trypsin 0.3 U/ml) was washed from the bath; see Examples). Time control responses to trypsin at 15, 45, 80 and 120 minute recovery were not significantly different from the initial control. (b) The recovery of trypsin sensitivity at 45 minutes was abolished by the protein trafficking inhibitor, brefeldin A ($10\mu M$) and

20

the translation inhibitor cycloheximide ($70 \mu\text{M}$). Both compounds had no effect on time control responses to trypsin. Values are mean \pm s.e. mean from 3-12 experiments (shown in parentheses). ($p < 0.01$).

- 5 Figure 12 is a schematic representation of the proposed broncho-protective role of PAR2 in the airways. The pathways denoted by the thick solid arrows (from activation of epithelial PAR2 by tryptase-like enzymes including trypsin to release of PGE_2 , and its subsequent activation of EP_2 receptors to initiate cAMP-dependent smooth muscle relaxation or other possible beneficial actions of
- 10 endogenously released PGE_2 are powerfully operational in the bronchi. The broken arrows indicate local sources of tryptase and tryptase-like enzymes and their relationship to inflammation. The same protective mechanisms would be activated by thrombin-mediated stimulation of epithelial PAR1.
- 15 Figure 13 is a light micrograph of a $15 \mu\text{m}$ cryostat section of part of the wall of a mouse bronchus, stained with haematoxylin/eosin. The darkly-stained convoluted layer is the epithelium (E) which lies just above the lightly-stained smooth muscle cells (SMC). Magnification: 40X.
- 20 Figure 14 depicts chart recordings showing the relaxation to the PAR1-activating peptide SFLLRN-NH₂ (TRAP), but not the PAR2-activating peptide, SLIGRL-NH₂ (PAR2-AP), in an isolated strip of epithelium-containing pig tracheal smooth muscle. SFLLRN-NH₂ (TRAP) caused a slow relaxation to near maximum to that of isoprenaline, which showed a similar slow time course. The tissue was

contracted to approximately 30% of its maximum contraction to acetylcholine (F_{\max}) with carbachol. During the break in the trace (20 min), the tissue also recovered its 30% F_{\max} level of active force spontaneously without washout.

5 Figure 15 depicts chart recordings showing relaxation to (A) PAR2 activating peptide (PAR2-AP) or SLIGRL-NH₂ and (B) trypsin in two isolated ring preparations of the rat bronchi with intact epithelium. In each case, the tissue was contracted to 50%-70% of their maximum contraction (F_{\max}) to acetylcholine (30 μ M). R_{\max} represents the maximum relaxation to isoprenaline.

10

Figure 16 depicts chart recordings showing relaxation to the PAR1 activating peptide SFLLRN-NH₂ (TRAP) in a single preparation of the guinea-pig isolated taenia coli, which initially contracted repeatedly with histamine (HIST; 1 μ M) to stable, submaximal levels of active force. At the breaks in the trace, the

15 preparation was washed thoroughly and left to recover for approximately 30 min prior to the next contraction with histamine. (A), control; (B), after treatment with propranolol (1 μ M) and prazosin (1 μ M) to block any relaxant adrenoceptors; (C), as for (B) except the NO synthase inhibitor, L-NOARG (100 μ M), was added as well; (D) as for (C) except the small conductance, Ca²⁺-activated K⁺ channel (SK)
20 inhibitor, apamin (0.1 μ M), was added as well.

Figure 17 is a chart recording showing relaxation to the PAR2 activating peptide (PAR2-AP or SLIGRL-NH₂) and the PAR1 activating peptide SFLLRN-NH₂ (TRAP) in an isolated strip of rat gastric fundus in which the mucosa was left intact. The

- 30 -

tissue was contracted to approximately 50% of its maximum contraction to KCl (50mM) with acetylcholine (Ach). Isoprenaline was added to obtain maximum relaxation.

- 5 Figure 18 is a chart recording showing the relaxation to the PAR1 activating peptide (SFLLRN-NH₂ or TRAP) [and to a smaller extent, PAR2-AP or SLIGRL-NH₂] in an isolated strip of longitudinal muscle of the human distal colon. The preparation was contracted to a stable level of active force with repeated additions of substance P (SP, w = wash). The breaks in the trace represent 10-15 min.
- 10 Apamin was left in contact with the preparation for more than 30 min.

- Figure 19 shows chart recordings illustrating relaxation to thrombin (a) and trypsin (b) in isolated human coronary arteries. Cumulative concentration-response curves (c, d) were generated in endothelium-intact (○) and -denuded (●) artery
- 15 ring segments contracted to approximately 50% of their maximum contraction (F_{max}) in response to 125 mM KCl ($KPSS_{max}$) with U46619 as depicted in (a) and (b). The degree of relaxation is expressed as the percentage reversal of the U46619 contraction and is mean \pm SEM from five separate experiments (patients).

- 20 Figure 20 shows the effects of inhibitors of nitric oxide on responses to thrombin (A), trypsin (B) and bradykinin (C) in human isolated coronary artery ring segments contracted to approximately 50% of their maximum contraction in response to 125 mM KCl with U46619. Responses to each enzyme were examined in control tissues (○) and tissues treated with a combination of N^G-nitro-L-arginine (100 μ M)

and oxyhaemoglobin ($20 \mu\text{M}$) (). Data are mean \pm SEM from 5-7 separate experiments (patients).

Figure 21 shows the responses to PAR1 and PAR2 activating peptides in human
5 isolated coronary artery ring segments contracted to approximately 50% of their
maximum contraction in response to 125 mM (KPSS_{max}) with U46619. Cumulative
concentration-response curves were generated to the human PAR1 activating
peptide, SFLLRN-NH₂, in endothelium-intact (\circ , $n=10$ from 5 patients) and-
denuded (\bullet , $n=5$ from 5 patients) preparations and to the human PAR2 activating
10 peptide, SLIGKV-NH₂, in endothelium-intact tissues (\blacksquare , $n=5$ from 2 patients). Data
are expressed as mean \pm SEM.

Figure 22 shows digitized traces of original chart recordings showing the effect of
desensitization to thrombin (a) and trypsin (b) on relaxation to the thrombin
15 receptor peptide ligand, SFLLRN-NH₂ (TRAP), in separate rings of human
coronary artery contracted to $\sim 50\%$ F_{max} with 3 nM (a) and 4 nM (b) final
concentrations of U46619. SP = substance P; ISO = isoprenaline; Throm =
thrombin; Tryp = trypsin (units of both enzymes given as U/ml). The time
calibration bar represents 20 min prior to the arrow. Tissues were incubated for at
20 least 2h with maximum concentrations of (a) thrombin and (b) trypsin, and then
washed prior to contraction with U46619.

Figure 23 shows the effect of thrombin desensitization on responses to the PAR1
activating peptide in human isolated coronary artery. Ring segments contracted to

- 32 -

approximately 50% of their maximum contraction in response to 125 mM (KPSS_{max}) with U46619 were either untreated (○) or desensitized to both thrombin and trypsin (●) before cumulative concentration-response curves to the human PAR1 activating peptide, SFLLRN-NH₂, were generated. Data are expressed as mean ± SEM (n=8, from 4 patients).

Figure 24 shows relaxation to the PAR1-activating peptide (A;TRAP) but not the PAR2 activating peptide (B;PAR2-AP) in two 2 mm long ring segments of isolated human bronchioles (approximately 500 μm internal diameter). Both segments were contracted to approximately 30% F_{max} with carbachol, 0.005% w/v BSA was added and then TRAP and PAR2-AP were cumulatively added. Only TRAP caused concentration-dependent relaxations up to a maximum of approximately 30% that of isoprenaline plus IBMX. Breaks in the traces represent 10 min.

Figure 25 shows relaxation to (A) thrombin and (B) trypsin in two separate 2 mm long ring segments of isolated human bronchioles (approximately 500 μm in internal diameter). The set-up procedure was as described in Figure 24. Both enzymes caused slow, activity-dependent relaxation of between 30 and 60% maximum relaxation to isoprenaline plus IBMX. The traces were interrupted (5-20 minute breaks) to depict rates of onset of relaxation and maximum responses.

Figure 26 shows the immunohistochemical localisation of PAR2 in mouse bronchi, and demonstrates that PAR2 and PAR1 mediates epithelium-dependent relaxation in isolated rings of this tissue.

- 33 -

- (a) Confocal photomicrograph showing PAR2 immunofluorescence to discrete epithelial cells (arrow) as well as smooth muscle cells (m) and fibroblasts (arrow head). In some epithelial cells, the fluorescence appeared concentrated within areas of the cytoplasm. Pre-absorption with the peptide sequence used to raise the mouse PAR2 antibody quenched the epithelial, smooth muscle and fibroblast fluorescence. The scale bar represents 10 μm .
- (b) An original, digitised chart recording of changes in isometric force in a single ring of mouse left bronchus with intact epithelium. The tissue was contracted to approximately 40% F_{max} to acetylcholine (Ach; 30 μM) with cumulative, titrated concentrations of carbachol. Note the change of gain, and that the force recovered spontaneously over the 15 minute break in the trace after maximum relaxation to SLIGRL-NH₂.
- (c) Removal of the epithelium with 0.1% v/v Triton X-100 abolished relaxation to SLIGRL-NH₂ and SFLLRN-NH₂ whereas the tissue could still sensitively relax to PGE₂.
- (d) Light photomicrographs of cross sections of mouse bronchi, showing that the 0.1% Triton X-100 perfusion technique removed the vast majority of columnar epithelial cells (arrows) with no microscopic evidence of damage to the underlying smooth muscle (m). Scale bar

- 34 -

represents 30 μm .

Figure 27 shows the mechanisms of PAR-mediated bronchodilatation.

- 5 (a) epithelium-; and
- (b) cyclooxygenase-dependent relaxations of mouse isolated bronchi to the PAR2 and PAR1 synthetic peptide ligands SLIGRL-NH₂ and SFLLRN-NH₂, respectively.
- 10 (c) relaxations to trypsin and thrombin in epithelium-intact preparations were similarly abolished by cyclooxygenase inhibition. Group data from similar experiments to that described in Figure 26, except that tissues were treated with indomethacin (3 μM) and aspirin (100 μM)
- 15 to block cyclooxygenase activity. All relaxations and contractions are expressed as percentages of the initial force to carbachol (40% F_{max}) regardless of treatment. Values on the graphs are mean \pm s.e.mean from 5-9 experiments, except aspirin (n=3). * P < 0.01. Note that the NO inhibitors had no effect on the relaxations to PAR1- and
- 20 PAR2-activating peptides.

Figure 28 shows that the PAR1- and PAR2-activating peptides SFLLRN-NH₂ and SLIGRL-NH₂ respectively, act at separate receptors to cause bronchial relaxation. Desensitisation to trypsin (■) but not to thrombin (▲) abolished the responses to

the PAR2 peptide, SLIGRL-NH₂ (a), whereas relaxation to the PAR1 peptide, SFLLRN-NH₂, was markedly inhibited following desensitisation to both enzymes (b). In both cases, (●) represents control responses. Values on the graphs are mean ± s.e. mean from 5-6 experiments. * P < 0.01

5

Figure 29 are graphical representations demonstrating that the PAR2 activating peptide SLIGRL-NH₂ [$\leq 400 \geq 2$] causes inhibition of bronchoconstriction *in vivo*. Original chart recordings (a, b) and grouped data (c, d) showing the effect of a 30 sec exposure to an aerosol of a 0.1 mg/ml solution of SLIGRL-NH₂ [$\leq 400 \geq 2$] on 5-HT (3nmol/kg i.v.)-induced changes in airway resistance (R_L; a, c) and dynamic compliance (C_{dyn}; b, d) in the anaesthetised rat. Not shown is the complete inhibition of bronchoconstriction to 5-HT lasting at least 45 min occurred when SLIGRL-NH₂ [$\leq 400 \geq 2$] was used at 1 mg/ml. Values are mean ± s.e. from n=3 experiments.

15

Figure 30 is a graphical representation showing digitised traces of original chart recordings of increases in I_{sc} to ATP, the PAR2 synthetic ligand; SLIGRL-NH₂ and PGE₂ in mouse trachea mounted in an Ussing Chamber. All drugs were applied on the apical surface.

20

Figure 31 is a graphical representation showing concentration-dependent increase in short circuit current (I_{sc}) in mouse trachea mounted on the Ussing Chamber (see methods). Cumulative concentrations of SLIGRL-NH₂ (■), SFLLRN-NH₂ (▲), GYPGKF-NH₂ (▼), PGE₂ (◆), ATP () and UTP (□) were added to the luminal

bath. Values on the graphs are mean \pm SEM from 5-6 experiments.

Figure 32 a graphical representation showing the effect of CFTR and dependent Cl^- Ca^{2+} channel inhibition by glibenclamide (100 μM : G) and DIDS (4, 4' -

5 diisothiocyanostilbene 2, 2' - disulphonic acid, 100 μM : D) respectively on (a) SLIGRL- NH_2 (30 μM), (b) ATP (10 μM) and (c) PGE_2 (10 μM). Digitised traces of original chart recordings for responses in mouse trachea mounted on an Ussing Chamber are shown. All drugs were applied on the apical surface.

10 Figure 33 a graphical representation showing a mechanism of chloride secretion component of I_{SC} : the effect of glibenclamide (100 μM ; G) alone or combined with 4, 4'-diisothiocyanostilbene 2, 2'-disulphonic acid (DIDs) (100 μM ; G+D) or DIDS (100 μM ; D) or combined with glibenclamide (100 μM ; D+G) on (a) PAR2 synthetic ligand SLIGRL- NH_2 (30 μM), (b) ATP (10 μM) and (c) PGE_2 (10 μM) in isolated
15 mouse trachea.

Figure 34 is a graphical representation depicting increases in I_{SC} to PAR2 and PAR1-activating peptides SLIGKV and SFLLRN, respectively in human bronchial epithelium. The maximal response of the tissue, elicited by isobutylmethylxanthine
20 is also shown.

Figure 35 is a diagrammatic representation showing cytoprotection by epithelium-derived factors.

- 37 -

Figure 36 is a graphical representation showing the effect of inhaled SLIGRL on LPS induced neutrophil recruitment in murine lungs.

Figure 37 is a graphical representation of digitised original chart recordings showing the smooth muscle relaxing effects of PAR1 and PAR2 peptide activators, SLIGKV and SFLLRN respectively and the PAR activating enzymes, thrombin (PAR1 selective) and trypsin (PAR2 selective) in isolated ring segments of monkey small bronchi. Traces are characteristic of similar tissues taken from four separate animals (two pigtail macaques; two cynomolgus). The experimental details are similar to those for the mouse isolated bronchi. Briefly, approximately 2 mm long rings of small bronchi were mounted on wire hooks. In each trace, half log concentrations are not depicted for clarity. In some cases PGE3 and isoprenaline (iso) were added to (1) show that these tissues were responsive to PGE2 and (2) to obtain maximum tissue relaxation.

15

Figure 38 is a graphical representation of cumulative concentration in response curves to PAR1-, PAR2- and PAR4-activating peptides.

Figure 39 is a diagrammatic representation of dual compartment model of PAR2 functionality in epithelial cells. PAR2, expressed by epithelial cells, serves to sense tryptic enzymes released by the epithelium itself during defensive reactions. Activation of PAR2 by these enzymes results in cytoprotection *via* the many means already alluded to in this patent. In contrast, mast cell tryptase, an enzyme potentially able to activate PAR2, cannot activate PAR2 because the epithelial

20

- 38 -

barrier prevents it from gaining access to the tops of epithelial cells where PAR2 is concentrated. However, if the epithelium is disturbed then mast cell tryptase gains access to PAR2, which it may chronically activate because there are no endogenous activators of this enzyme. In contrast, epithelia produce proteins that

5 inhibit epithelium-derived enzymes like trypsin. Hence trypsin can only mediate short-term, protective effects. Also indicated is that some epithelial cells may express PAR2 on their bottom surfaces, perhaps mediating some effects of mast cell tryptase. To date, PAR2s have never been observed in this position in airway tissues of any species.

10

Although the present invention is particularly directed to inhibition of bronchoconstriction and/or inflammation, the subject invention extends to PARs such as PAR2 orchestrating a wide range of bronchoprotective responses. In particular, the present invention extends to the development of technology

15 stemming from the recognition that endogenous activators (e.g. trypsin) and PARs (e.g. PAR2) are co-localised in the epithelium and act as an amplifier of a PAR (e.g. PAR2) protective mechanism. Reference to "inflammation" includes reference to oedema.

20

- 39 -

Abbreviations used herein are as follows:

Ach	acetylcholine
ATP	adenosine 5'-triphosphate
5 $F_{\max}/KPSS_{\max}$	maximum force of contraction (grams)
FITC	fluorescein isothiocyanate
HbO	oxyhaemoglobin
IBMX	isobutyl methylxanthine
Indo	indomethacin
10 KPSS	potassium -containing physiological salt solution
L-NOARG	N ^G -Nitro-L-arginine
NO	nitric oxide
PACAP	Pituitary adenylyl cyclase activating peptide
PAR	Protease activated Receptor
15 PAR2-AP	PAR2 Activating Peptide
SK	Ca ²⁺ -activated K ⁺ channel
To	optimal tissue stretch to give maximum active force
TRAP	Thrombin Receptor-Activating Peptide, SFLLRN- NH ₂
VIP	vasoactive intestinal peptide

EXAMPLE 1

Materials and methods

Chemicals

5 Acetylcholine chloride, bovine serum albumin, bradykinin triacetate, carbachol, cycloheximide, haemoglobin (bovine plasma), histamine dihydrochloride indomethacin, (-)-isoprenaline, N^G-nitro-L-arginine, substance P (acetate salt) and α-thrombin (bovine serum) were obtained from Sigma (MO, U.S.A.). Actinomycin D, apamin, aspirin, brefeldin A, carbaprostacyclin, isobutylmethyl xanthine (IBMX),
10 prostaglandin ethanolamide, 9, 11-dideoxy-9α 11α-methanoepoxy-prostaglandin F2α (U46619), prazosin hydrochloride and nifedipine were from Sapphire Bioscience (N.S.W. , Australia). Trypsin (bovine pancreas) was from Worthington Biochem (NJ, U.S.A.) and SLIGRL-NH₂, SLIGKV-NH₂ and SFLLRN-NH₂ were obtained from Auspep (Vic, Australia).

15

Stock solutions of haemoglobin (1 mM) were dissolved in 0.9% w/v NaCl and then reduced with sodium dithionite (Na₂S₂O₄). Excess Na₂S₂O₄ was removed by passing the solution through a Sephadex PD10 size exclusion column.

20 Stock solutions of brefeldin A (1 mM), carbaprostacyclin (1 mM), prostaglandin E₂ (1 mM), nifedipine (10 mM) and U46619 (1 mM) were in absolute ethanol, while those for indomethacin (100 mM) and N^G-nitro-L-arginine (100 mM) were in Na₂CO₃ and NaHCO₃, respectively. All subsequent dilutions of these drugs were in distilled water, as were solutions of all other drugs.

25

In vitro studies

The right and left main bronchi and their first order branches of specific pathogen-free (SPF) Balb/c mice (15-20 g; either sex), Hartley tricolour guinea-pigs (300-400 g; male) and Sprague-Dawley rats (200-350 g; either sex), all killed by either cervical dislocation or overdosed (i.p.) with sodium pentobarbitone, were cleared of surrounding connective tissue, nerves and blood vessels under a dissecting microscope and placed in cold, carbogenated (95% v/v O₂, 5% v/v CO₂) Krebs solution (Kemp and Cocks, 1997). Human airway preparations (0.5-1 mm in external diameter) were dissected from lungs of cancer patients undergoing thoracotomy at The Royal Melbourne Hospital, Melbourne, Australia. The epithelium was removed from some bronchi either by mechanical abrasion of the luminal surface (guinea-pig) or by brief, gentle intraliminal flushing of the airways with Krebs containing 0.1% v/v Triton-X100 (mouse and rat). In each case, removal of the epithelium was verified histologically in 8 µm formalin-fixed, paraffin sections stained with haematoxylin and eosin. Ring segments (approximately 2mm long) of bronchi and bronchioles were mounted in Krebs (37°C) on stainless steel wires (40 µm) in dual channel (5 ml) Mulvany-Halpern myographs (JP Trading, Aarhus, Denmark) to record changes in isometric force (Kemp and Cocks, 1997). After equilibration at a passive force between 0.2 g and 0.3 g, tissues were contracted to their maximum levels of active force (F_{\max}) with acetylcholine (30 µM), thoroughly washed with Krebs and allowed to return to baseline. Various drugs or their vehicles were then added and 30 min later all tissues were contracted to approximately 40% F_{\max} with titrated concentrations of carbachol (10-500 nM). The L-type voltage-operated Ca²⁺ channel inhibitor, nifedipine (0.3 µM) was added to all mouse and rat tissues after obtaining F_{\max} to

control characteristic phasic contractile activity with carbachol. When a stable level of active force to carbachol was obtained, tissues were exposed to cumulatively increasing concentrations of the PAR1 and PAR2-activating enzymes, thrombin (bovine serum, Sigma, MO, USA) and trypsin (bovine pancreas, 3x crystallised, Worthington Biochem, NJ, USA) respectively, and their synthetic tethered ligand peptide sequences, SFLLRN-NH₂ [$\langle 400 \rangle 1$] and SLIGRL-NH₂ [$\langle 400 \rangle 2$] (each >95% purity; Auspep, Parkville, Australia).

To assess the effect of enzyme-mediated receptor desensitisation on responses to the synthetic peptides, mouse bronchi were allowed to recover to their initial level of active force to carbachol following cumulative concentration-responses curves to trypsin (0.001-0.3 U/ml) or thrombin (0.001-0.3 U/ml) but with enzymes still present in the myograph chamber. When the force again reached a steady level, they were tested for desensitisation with maximum concentrations of trypsin and thrombin (0.3 U/ml). If no response occurred the tissues were then exposed to cumulative concentrations of either SLIGRL-NH₂ [$\langle 400 \rangle 2$] or SFLLRN-NH₂ [$\langle 400 \rangle 1$] (0.1-30 μ M).

The time course and mechanism of PAR2 resensitisation were determined in mouse bronchi either left untreated (time control) after acetylcholine washout or treated with trypsin (0.3 U/ml at 2 min intervals) over a period of 20 to 30 min. Tissues were then contracted with carbachol to approximately 40% F_{\max} and exposed to trypsin (0.3 U/ml) at 0, 15, 45, 80 or 120 min after washout. Time controls to trypsin in non-desensitised tissues were not different at any of the times examined. The protein trafficking inhibitor, brefeldin A (10 μ M) and the protein translation blocker, cycloheximide (70 μ M), were then used to explore the

- 43 -

mechanism underlying PAR2 resensitisation following desensitisation with trypsin. In these experiments, trypsin-desensitised tissues were either left untreated (control) or treated with brefeldin A or cycloheximide before re-exposure to trypsin (0.3 U/ml) at 45 min.

5

In vivo studies

Male Sprague-Dawley rats (8 weeks) were anaesthetised (xylazine 10 mg/kg, ketamine 100 mg/kg and 50 mg/kg each 30 min thereafter, i.p.) and cannulae
10 were placed in the trachea, carotid artery and jugular vein. Spontaneous breathing was stopped by an intravenous injection of pancuronium bromide (0.4 mg/kg and 0.2 mg/kg each 30 min thereafter) and rats were ventilated (tidal volume 8 ml/kg at 90 breaths/min, SAR-830 ventilator, CWE Inc., Ardmore, USA). Breath-to-breath measurement of airway resistance (R_L) and dynamic compliance
15 (C_{dyn}) were calculated from flow and transpulmonary pressure recordings (PMS800, Mumed, London, UK). Flow was measured over the tracheal cannula (Fleisch pneumotachograph, Lausanne, Switzerland) and transpulmonary pressure was measured with a differential pressure transducer, one end being connected to the outlet of the tracheal cannula, the other to an air-filled cannula
20 inserted in the oesophagus. A rectal probe was used to monitor body temperature. Serotonin (5-HT; 0.3 mg/kg i.v.) was administered as a bolus dose at 5 min intervals until reproducible changes in R_L and C_{dyn} were obtained. Prior to each 5-HT challenge, lungs were hyperinflated once (by delivering twice the tidal volume) to prevent and reverse atelectasis. SLIGRL-NH₂ [$<400>2$], the scrambled
25 peptide LSIGRL-NH₂ [$<400>4$] (both 0.1 mg/ml) and their vehicle controls (saline) were then delivered for 30 sec as aerosols generated by an ultrasonic nebuliser

(AeroSonic 5000, DeVilbiss, Somerset, USA) in series with a second ventilator and the response to 5-HT determined 5 min later.

Data analysis

5

All cumulative responses (relaxations and contractions) were normalised as percentages of the initial level of active force to carbachol. Results are presented as mean \pm s.e. mean and pEC₅₀ (sensitivity) values were calculated by fitting concentration-response curves to a four parameter logistic function (Kemp and
10 Cocks, 1997) using Graphpad Prism (version 2.0). Statistical comparison of mean pEC₅₀ and maximum response (R_{max}) values were compared by two-tailed unpaired Student's *t*-tests or one way analysis of variance (ANOVA) with Tukey-Kramer's *t*-tests for multiple comparisons. *P*<0.05 was accepted as significant. Unless specified, all averaged data are from n>5 experiments.

15

Immunohistochemistry *Mouse*

Fresh frozen, paraformaldehyde-fixed sections (14 μ m) of mouse bronchus were incubated with a rabbit antiserum directed against the carboxyl-terminal of mouse
20 PAR2 (CSVKTSY [\leq 400 \geq 5]) at a dilution of 1:500 for 48 h, washed with phosphate-buffered saline (PBS) and then incubated with a biotinylated donkey anti-rabbit antiserum (Amersham) for 2 h, washed again with PBS and then labelled with FITC-conjugated streptavidin (Amersham) all at room temperature. After a final wash in PBS, the sections were mounted in buffered glycerol and
25 viewed under a Biorad MRC1000 confocal scanning laser system installed on an Olympus IMT2 microscope with a krypton/argon laser. Visualisation of FITC was

- 45 -

achieved using a 488nm excitation filter and a 522/535nm emission filter. Images of 768x612 pixels were then processed using Adobe Photoshop software. No staining was observed when the antiserum was preabsorbed with the immunising peptide sequence (10 μ M at 4°C for 24 h).

5

Human

Paraffin sections (3 μ m) were dewaxed and exposed to the rabbit anti-PAR2 antiserum as described above. After 24 h exposure, a monoclonal mouse
10 antibody directed against human trypsin (ogen) (Chemicon, MAB1482) was also applied. After a further 24 h exposure to both probes, binding of the rabbit anti-PAR antiserum was localised as described above, while trypsin(ogen) was localised using a donkey anti-mouse antiserum conjugated to rhodamine. The expression of PAR2 and trypsin(ogen) was examined under epifluorescence using
15 a Zeiss Axioskop microscope equipped with separate filters for FITC and rhodamine fluorescence. Photographs were taken on Kodak Ectachome T160 film and subsequently scanned on a Macintosh computer using a slide scanner (Nikon). The separate images of FITC (green) or rhodamine (red) fluorescence were overlayed with Adobe Photoshop software, using obvious reference points to
20 correctly align the images.

EXAMPLE 2

Activation of PAR in bronchi of the guinea-pig and mouse

Guinea-pigs of either sex (250-300g) were killed in initial experiments by CO₂ asphyxia, and in later experiments by a blow to the head. Where a blow to the head was used, great care was taken to ensure that the airways did not aspirate blood. Mice (Balb/c, male and female, 20-25g) were killed by cervical dislocation and exsanguination. In both cases, the left and right bronchi were exposed and carefully dissected free from surrounding connective tissue using a dissecting microscope, excised and placed in cold, physiological bicarbonate-buffered Krebs solution of the following composition (in mM): (Na⁺ 144, K 5.9, Ca²⁺ 2.5, Mg²⁺ 1.2, Cl⁻ 128.7, HCO₃⁻ 25, H₂PO₄⁻ 1.2, SO₄²⁻ 1.2 and glucose 11 (Stork and Cocks, 1994a). This solution was continuously gassed with a mixture of 95% v/v O₂, 5% v/v CO₂ to maintain pH at 7.4 and adequate pO₂ of the solution. An approximately 3mm long ring was cut from each bronchus. In order to maximize sensitivity, some guinea-pig airways were cut as bronchial spirals, which brings several segments of smooth muscle into series.

For the guinea-pig, the preparations were suspended vertically on two stainless steel wire hooks in organ baths containing warm (37° C), gassed Krebs solution. One wire was attached to a micrometer-driven support leg, the other to a force-displacement transducer to record changes in force.

Mouse bronchus preparations were carefully mounted horizontally on fine (40 µm) stainless steel wires attached to the jaws of a Mulvany-Halpern myograph.

- 47 -

After 60 min at 37° C, all rings were stretched to 0.5g passive force, which had been determined in preliminary experiments to be optimal, and allowed to recover from that stretch for a further 30 min. Maximum contraction (F_{max}) in each tissue was then determined with exogenously applied acetylcholine (ACh; 30 μ M) followed by washout. A further 30 min equilibration time was allowed before the tissues were actively contracted to between 20% and 60% of their individual F_{max} values with titrated concentrations of carbachol (10-100nM). When these contractions maintained steady plateaus, cumulative half-log concentrations or units of enzyme activity of trypsin, thrombin, SLIGRL-NH₂ (PAR2-AP), SFLLRN-NH₂ (TRAP) prostaglandin E₂ (PGE₂) and isoprenaline were added. In some cases, tissues were treated with a range of drugs prior to contraction to approximately 50% F_{max} . These included the cyclooxygenase inhibitors indomethacin and aspirin, the nitric oxide (NO) synthase inhibitor N^G-nitro-L- (L-NOARG), the NO scavenger oxyhaemoglobin (HbO), and the L-voltage-operated Ca²⁺ channel inhibitor nifedipine.

The luminal surface of some rings of bronchi were mechanically abraded with a tapered wooden stick to remove the epithelium. The integrity of the epithelium and underlying smooth muscle, as well as the effectiveness of epithelium removal, were confirmed histologically using 15 μ m cryostat sections of the bronchi stained with haemotoxylin/eosin.

Whilst it was possible to surgically abrade the epithelium in the guinea pig to test the role of the cells in the PAR2-mediated relaxation response, as described below, many of the animals had large amounts of mucus present in the airways

- 48 -

during dissection. Guinea-pigs are not pathogen-free, and an abnormally high amount of mucus can be a sign of airway infection. In view of the inventors' hypothesis that PAR2 might be an intrinsic protective mechanism which may be compromised during airway infection, experiments were therefore designed using
5 specific pathogen-free Balb/c mice. If PAR2 was shown to mediate bronchorelaxation responses in this species, it would then be possible to test whether PAR2 and PAR1 were involved in the pathogenesis of asthma.

When bronchial smooth muscle relaxation or contraction mediated by PAR2
10 and PAR1 in the mouse was investigated, it was found that most preparations developed spontaneous, phasic contractions to carbachol, a cholinergic agonist similar to methacholine, which were superimposed on the tonic 20%-60% F_{max} responses. These contractions were rhythmical, and often of large amplitude. Furthermore, they were maintained for variable times before suddenly returning
15 to near-basal levels of active force, as shown in Figure 2. This instability, combined with the spontaneous activity, resulted in difficulty in assessing relaxations. It was also difficult to place the contraction to carbachol at a predetermined percentage of F_{max} , since it tended to be all-or-nothing until the near-maximum of the curve was reached. However, with maximum
20 concentrations of the relaxing agents, and with appropriate time controls, fast onset and rapid near-maximum relaxations to PAR2-AP were routinely obtained, as shown in Figure 4.

EXAMPLE 3

Effect of nifedipine

The effect of the L-type voltage-operated Ca^{2+} channel inhibitor, nifedipine, on
5 the bioassay system for bronchodilators in the mouse was also examined.
Results for the human coronary arteries are shown in Figure 3. Nifedipine (10
nM; see panel D) blocks both the spontaneous contractions and those which
develop in response to U46619. Such treatment allows more accurate and valid
measurement of relaxations at pre-set levels of now stable active force (Stork
10 and Cocks, 1994a). Nifedipine (0.3 μM) also abolished the phasic contractions
of the bronchi to carbachol, and resulted in the maintenance of stable levels of
tonic, active force at any predetermined level. These results are shown in
Figure 4. Development of similar spontaneous activity to that shown in Figure 3
was observed. However, even with such activity present, relaxation in response
15 to both PAR2-AP and trypsin appeared to have occurred since active force
remained constant for the time taken to obtain the relaxation to each agonist
(see "TIME CONTROL" panel). Nifedipine markedly inhibited the contraction to
carbachol, so that higher concentrations were required to restore force to
control levels. Under these conditions, however, phasic activity was absent and
20 unequivocal concentration dependent relaxations to PAR2-AP were readily
demonstrated. Under these conditions, PAR2-AP routinely caused well defined,
concentration-dependent relaxation.

EXAMPLE 4

Effect of deudation of the epithelium

- 5 Whenever attempts to remove the epithelium from mouse bronchi or trachea were made, they invariably damaged the underlying smooth muscle, since all rings treated in this manner failed to contract to ACh. Therefore, studies were conducted using the guinea-pig to obtain information as to the possible role of the epithelium in mediating bronchial smooth muscle relaxation to PARs.
- 10 Concentration dependent relaxations to PAR2-AP were observed in six out of thirteen bronchial rings in which the epithelium was intact; the remaining seven tissues either gave no response or small contractions to PAR2-AP. In the same number of epithelium-denuded rings (n=6) from animals where PAR2-AP caused relaxation (An=6), PAR2-AP either caused a small contraction or no
- 15 response, as seen in Figure 5. In a further experiment where spiral strips rather than rings were used, PAR2-AP caused relaxation which was clearly concentration- and epithelium-dependent, as shown in Figure 6. The presence and absence of the epithelium was histologically confirmed. SFLLRN-NH2 (TRAP) only caused concentration-dependent contractions, which were
- 20 unaffected by removal of the epithelium.

EXAMPLE 5

Mediators of epithelium-dependent broncho-relaxation

Figure 7 shows how isolated mouse bronchi were set up to measure relaxation sensitively. After an initial passive stretch to 0.5g (Ti) and recovery, each ring was contracted with acetylcholine (Ach; 30 μ M). The contraction was taken as the tissue maximum and referred to as F_{max} . After washout (w) and recovery, the tissue was then contracted to approximately 40% F_{max} with titrated, cumulative concentrations of carbachol, resulting in a change in gain. When the contraction to carbachol reached a stable plateau, cumulative, half-log molar concentrations of PAR2-AP and TRAP were added. The results demonstrate that both PAR2-AP and SFLLRN-NH2 (TRAP) caused powerful concentration-dependent relaxations in this preparation. These responses were unaffected by the combined treatment with the NO blockers L-NOARG (100 μ M) and HbO (20 μ M), but were abolished by the cyclooxygenase inhibitors indomethacin (3 μ M) and as pirin (100 μ m), as shown in Figure 8. TRAP was less effective as a mediator of relaxation, and responses to this ligand were converted to concentration-dependent contractions by indomethacin and aspirin. This effect was partially blocked by L-NOARG and HbO, as seen in Figure 8. Under the same bioassay conditions, trypsin cause activity-dependent relaxation which, as for PAR2-AP, was also blocked by indomethacin. By contrast, thrombin caused only poor indomethacin sensitive relaxation at high concentrations which, like TRAP, were converted to contractions by indomethacin. These results are shown in Figure 8. Continual exposure of the mouse bronchi to high

- 52 -

cumulatively increasing concentrations of PAR2-AP (up to 100 μ M) for 2h allowed by washout had no effect on the sensitivity or maximum response to subsequent addition of PAR2-AP. All occurrences of relaxation were due to an indomethacin- and aspirin-sensitive mechanism, with no role for NO.

5 Indomethacin and aspirin also converted the relaxation in response to SFLLRN-NHz (TRAP) to a contraction. Thrombin gave little or no relaxation in the absence of indomethacin, but like TRAP caused a contraction in its presence. In contrast, the response to PAR2-AP was virtually abolished after continual exposure of the tissue to a maximum concentration of trypsin, but not thrombin,
10 as shown in Figure 9, indicating that trypsin and PAR2-AP activated the same receptor. PGE₂ caused potent and maximum relaxation of the mouse bronchi, as shown in Figure 10.

EXAMPLE 6

15 Turnover of PAR2

Turnover mechanisms are critical regulators for cells to maintain their responsiveness to PAR-activating enzymes. Therefore, if PARs are to be effective mediators of bronchoprotection, they should be rapidly replaced by
20 new receptors once enzymically cleaved. The inventors examined turnover of functional PAR2 in the mouse bronchi since, unlike PAR1, they were purely inhibitory.

Mouse bronchi were prepared as described in Example 1. Recovery of

PAR2-mediated relaxation to trypsin following desensitization to the compound was then measured. The results, presented in Figures 11a and 11b, showed that bronchial PAR2s were replaced very rapidly following activation with trypsin. Thus, in each experiment, complete recovery of maximum relaxation to trypsin occurred 30 min after an initial desensitising concentration of trypsin. This recovery was abolished by the protein trafficking inhibitor brefeldin A (10 μ M) or the protein synthesis inhibitor cycloheximide. The data show that PAR2s were rapidly replaced after activation with trypsin, since relaxation to trypsin returned to near-control levels within 45 minutes after the tissue was desensitised to trypsin. This complete and rapid recovery was abolished by the protein trafficking inhibitor, brefeldin A (10 μ M) and the translation inhibitor, cycloheximide (70 μ M; Figure 11b). Equally rapid turnover of cloned PAR2 expressed in selected cell lines has been shown to be dependent on both de novo synthesis of new protein as well as trafficking of preformed receptors from intracellular pools. These data imply that new, fully intact PAR2s are vital for normal functioning of the airways.

EXAMPLE 7

PAR-mediated airway relaxation occurs in rats and pigs

20

The airways of both rats and domestic pigs also relaxed when PARs were activated, as shown in Figures 14 and 15. Pig tracheal muscle strips of approximately 2 mm x 2 mm in size and with mucosa were prepared by dissecting away overlying cartilage. Strips were suspended in Krebs solution

- 54 -

under 1g passive tension, and contracted to approximately 30% maximal contraction with carbachol (40 μ M). The PAR1 activating peptide TRAP, but not the PAR2 activating peptide, PAR2-AP, produced slow onset, near maximal relaxation of the tissue comparable in extent to that induced by isoprenaline, as indicated in Figure 14.

Bronchi from Male Sprague-Dawley rats prepared as rings in the same way as for mouse bronchi produced results that were qualitatively similar to those observed in the mouse, as indicated in Figure 15. The PAR1 activating peptide SFLLRN-NHz (TRAP) only caused a contraction, whereas thrombin caused a small relaxation.

These observations show that the bronchodilatory principle is general, and the inventors have demonstrated this in four species, including two phylogenetically-related species (mouse and rat) and two more distantly-related species, the guinea-pig and domestic pig. As shown in Example 10, these findings also extend to human airways.

Example 8

PAR mediated relaxation occurs in non-airway tissue, and can utilize effector mechanisms different to those in the mouse bronchus

(A) Guinea-pig taenia coli

2 cm strips of taenia coli with intact Auerbach's plexus, but which had been stripped of the mucosa, were suspended in Kreb's solution under 1g passive

- 55 -

tension, and contracted with histamine ($1\ \mu\text{M}$) to induce active tension.

This tissue relaxed in response to TRAP in a concentration-dependent manner.

The relaxation was not suppressed by the cyclooxygenase inhibitor indomethacin
5 ($3\ \mu\text{M}$), the nitric oxide (NO) inhibitor L-NOARG ($100\ \mu\text{M}$), the beta-adrenoceptor
antagonists propranolol ($1\ \mu\text{M}$) or the alpha-adrenoceptor antagonist prazosin ($1\ \mu\text{M}$), thus precluding prostaglandin, NO, and adrenergic mechanisms. However,
the relaxation was inhibited by pre-treatment with the small conductance Ca_v4 -
activated potassium channel (SK) inhibitor, apamin ($100\ \mu\text{M}$), as shown in Figure
10 16. There was no relaxation to ATP in the presence of apamin, indicating the
selectivity of apamin for SK channels. These data indicate that the PAR-activated
protective mechanism can couple to several response transduction systems, and
is not limited by the availability of cyclooxygenase metabolism. The exact
mediator of the apamin sensitive relaxation in this tissue is unknown, but
15 candidates include the neuropeptides PACAP and VIP and the purine ATP, which
are thought to directly or indirectly open SK channels that mediate relaxation.

(B) Rat gastric fundus

20 Longitudinal strips of gastric fundus from male Sprague-Dawley rats were
suspended under 1g passive isometric tension in Krebs solution.

This tissue related to both PAR1 and PAR2 activating peptides, as shown in
Figure 17.

- 56 -

(C) Human distal colon

Human distal colon strips obtained at bowel resection were suspended at 1g passive isometric force and contracted with substance P ($30 \mu\text{M}$) to maintain a steady level of active tension.

This tissue relaxed in an apparently apaminin sensitive manner to SFLLRN-NH₂ (TRAP) and to a lesser extent PAR2-AP. Thrombin, however, did not result in relaxation in this tissue, as depicted in Figure 18.

10

EXAMPLE 9**PAR-mediated relaxation in human coronary arteries**

Human distal right coronary arteries (2-3 mm o.d.) were obtained from the explanted hearts of nine patients undergoing heart transplantation at the Alfred Hospital, Melbourne, Australia. Six patients were diagnosed with end-stage dilated cardiomyopathy, two with congenital septal defects and one with ischaemic heart disease.

Arteries were isolated immediately after explantation and transported to the laboratory in ice-cold Krebs solution (composition (mM): Na⁺ 144, Cl⁻ 128.7, HCO₃⁻ 25, K⁺ 5.9, Ca²⁺ 2.5, Mg²⁺ 1.2, H₂PO₄⁻ 1.2, SO₄²⁻ 1.2 and glucose 11). 3 mm ring segments, some with the endothelium removed by abrasion of the luminal surface with a filter paper taper moistened with Krebs solution, were mounted between two parallel, stainless steel wire hooks in 30 ml organ baths containing Krebs solution maintained at 37°C and continuously bubbled with 95% v/v O₂, 5% v/v CO₂. One

25

- 57 -

hook was attached to a micrometer-adjustable support leg and the other to an isometric force transducer (Grass Instruments, model FT03C) to record changes in isometric, circumferential force which were amplified and displayed on flat bed chart recorders (W & W Scientific Instruments).

5

Following a 60 min equilibration period, passive force (5g) was applied to the artery rings, which were then allowed to recover for 30 min before again being stretched to 5g. After a further 30 min, rings were exposed to 125 mM KCl (isotonic) Krebs solution (KPSS; (Drummond & Cocks, 1996)) to obtain a maximum contraction for each artery ring (KPSS_{max}). The KPSS was then replaced with normal Krebs solution and the tissues allowed to return to their optimal passive force level over 0-60 min. Nifedipine (0.3 μ M) and indomethacin (3 μ M) were added to inhibit spontaneous contractile activity (Stork & Cocks, 1994a) and prostanoid release, respectively.

15

(A) Responses to PAR activators

Aortic ring segments were contracted to approximately 50% KPSS_{max} with titrated concentrations of the thromboxane A₂ mimetic, U46619 (1 to 10 nM). Once the U46619-induced contraction had reached a stable level, cumulative concentration-response curves to thrombin and trypsin (0.0001 to 1 U/ml, or the human PAR1 activating peptide (SFLLRN-NH₂), the human PAR2 activating peptide (SLIGKV-NH₂) or the mouse PAR2 activating peptide (SLIGRLN-H₂) (0.01 to 100 μ M) were generated in the presence of bovine serum albumin (BSA; 0.005%). At the completion of each curve, maximum endothelium-dependent and -independent relaxation for each ring segment was determined with the addition of substance

25

- 58 -

P(3 nM) and isoprenaline (1 μ M), respectively.

(B) Effect of nitric oxide inhibitors

- 5 To examine the contribution of nitric oxide (NO) to PAR-mediated relaxation, aortic ring segments were either left untreated or were treated with the endothelial NO synthase inhibitor, L- NOARG; (100 μ M), the NO scavenger, HbO (20 μ M), or a combination of these agents, before the U46619-induced contraction.

10 (C) Desensitization experiments

- Tissues were either left untreated or were treated with cumulative additions of one of thrombin (0.1 U/ml) or trypsin (0.1 U/ml) every 30 min for 2 h in the presence of BSA (0.005% w/v). Tissues were then washed thoroughly with Krebs solution and
- 15 contracted to approximately 50% KPSS_{max} with U46619. Tissues were then exposed to the enzyme (0.1 U/ml) with which they had previously been treated until no further relaxation was observed. Importantly, the tissues were washed with Krebs solution, containing an appropriate concentration of U46619 to maintain the precontraction, between treatments with each activating enzyme. This ensured
- 20 that receptor desensitisation was not masked by occupation of the receptor by the tethered ligand sequence. Once desensitisation was achieved, cross-desensitisation was investigated by addition of the enzyme (0.1 U/ml) not used in the desensitisation process. Following this, cumulative concentration-response curves to the mouse PAR1 activating peptide, SLIGRL-NH₂, were
- 25 generated. Again, substance P(3 nM) and isoprenaline (1 μ M) were then added to determine maximal endothelium-dependent and -independent relaxations,

respectively.

(D) PAR-mediated responses

5 Thrombin (0.001 to 0.1 U/ml) and trypsin (0.01 to 1 U/ml) each caused rapid, enzyme activity-dependent relaxations of U46619-contracted human coronary artery rings, which were abolished upon removal of the endothelium, as shown in Figure 19. Sensitivity (pEC_{50} , log U/ml) and maximum (R_{max} % contraction reversal) values for thrombin were 2.5 ± 0.2 and $88.9 \pm 4.9\%$, respectively ($n=5$, from five
10 patients). Relaxations to trypsin had a similar maximum ($88.1 \pm 2.9\%$) to that for thrombin, but a significantly decreased ($P<0.05$) sensitivity (pEC_{50} 1.7 ± 0.1) ($n=5$, from five patients).

The endothelial NO synthase inhibitor, L-NOARG (100 μ M), in combination with the
15 NO scavenger, HbO₂ (20 μ M), significantly decreased both the sensitivity and maximum relaxation ($P<0.05$) of thrombin (pEC_{50} 1.0 ± 0.4 , R_{max} $14.2 \pm 7.1\%$; $n=5$, from five patients) and trypsin (pEC_{50} 1.3 ± 0.2 , R_{max} $17.2 \pm 10.7\%$; $n=5$, from five patients), as shown in Figures 20A and 20B, respectively. For both enzymes, the effect of L-NOARG in combination with HbO₂ was not significantly different from
20 that of either HbO₂ or L-NOARG alone. The effect of these NO inhibitors on PAR-mediated responses was also not significantly different to their effect on bradykinin ($n=7$, from seven patients) as shown in Figure 20C. Thus, as with other endothelium dependent dilators of human coronary arteries, PAR-mediated relaxations appear to be mediated predominantly by endothelial cell-derived NO.

- 60 -

The PAR1 activating peptide, SFLLRN-NH₂, also caused potent relaxation of precontracted human coronary artery segments, with pEC₅₀ (-log M) and R_{max} values of 6.9 ± 0.1 and $95.2 \pm 1.3\%$ (n=10, from five patients), respectively. This relaxation was abolished by endothelium denudation, as shown in Figure 21. In contrast, responses to the human PAR2 activating peptide (SLIGKV-NH₂) were significantly less (R_{max} $39.9 \pm 11.0\%$; n=5, from two patients). Interestingly, the mouse PAR2 activating peptide, SLIGRL-NH₂, which has a similar sequence to the human PAR2 activating peptide and has been shown to be equally active on PAR2 in other preparations (Blackhart *et al*, 1996), caused no relaxation.

10

(E) Desensitization of PARs

Desensitisation of tissues with either thrombin or trypsin caused loss of responsiveness to maximum relaxation-inducing concentrations of both enzymes, as shown in Figures 22a and 22b, indicating that the receptor(s) involved are activated by either of these enzymes. Interestingly, under these desensitizing conditions, the maximum response to SFLLRN-NH₂ was unaffected (R_{max} 92.0 ± 5.0), although there was a small, but significant ($P < 0.05$) decrease in sensitivity (pEC₅₀ 7.0 ± 0.1 vs 6.4 ± 0.2 ; n=8, from 4 patients), as illustrated in Figure 23.

20

This study is the first to show functional evidence of the presence of PAR-like receptors in isolated human coronary arteries. While the presence of mRNA encoding the first thrombin receptor, PAR1, has previously been reported in

- 61 -

endothelial cells of human abdominal aorta (Nelken *et al*, 1992), others have demonstrated that the presence of protease-activated receptor mRNA does not necessarily correlate with tissue responsiveness (Saifeddine, 1996). Previous evidence for functional PAR in human endothelial cells has been limited to the measurement of calcium fluxes in umbilical vein endothelial cells (Ngaiza, 1991; Kruse, 1995). However, it is important to examine the functional responses mediated by these receptors, and the studies described herein provide evidence that activators of PAR cause powerful, endothelium-dependent relaxation of human coronary arteries *in vitro*.

10

As has been demonstrated in the vasculature of the rat (Saifeddine *et al*, 1996) and pig (Hwa *et al*, 1996), the present studies show that U46619-contracted human coronary artery ring preparations were induced to relax by both thrombin and trypsin. However, only the peptide fragment corresponding to the human PAR1 tethered ligand sequence (SFLLRN-NH₂) was fully active in this preparation, while the PAR2 tethered ligand sequence (SLIGKV-NH₂) induced only a partial reversal of the U46619-induced contraction at comparably high concentrations.

Responses to both thrombin and trypsin were entirely dependent on the presence of an intact endothelium, and were virtually abolished by a combination of L-NOARG-mediated inhibition of endothelial NO production and scavenging of residual NO by HbO, indicating that PAR induced relaxations were mediated by endothelium-derived NO. The degree of inhibition was similar to that observed with bradykinin in this study, and is consistent with other reports that

20

endothelium-dependent relaxation of human coronary vessels is mediated predominantly by NO for agents including bradykinin (Kemp & Cocks, 1997) and substance P (Chester *et al*, 1990). Others have also shown that PAR-mediated vasodilatation in rat (Muramatsu *et al*, 1992), pig (Tesfamariam *et al*, 1993) and
5 dog (Tesfamariam, 1994) vessels is due to endothelial cell-derived NO. In contrast to previous reports which showed that thrombin contracted endothelium-denuded preparations of coronary artery from dog (White, 1994; Tesfamariam, 1994) and pig (Glusa & Markwardt, 1988), neither thrombin nor trypsin induced contraction of endothelium-denuded human artery preparations in the present
10 study. The lack of contraction to thrombin may be explained by the observation that mRNA for PAR1 was present only in endothelial cells in normal, non-atherosclerotic arteries (Nelken *et al*, 1992). Whether thrombin or the PAR1 activating peptide can cause contraction of endothelium-free vessels obtained from patients suffering from atheroma is of interest, since Nelken *et al*,
15 (1992) also located PAR1 mRNA in smooth muscle cells in affected vessels. The observations suggest that both enzymes mediate relaxation by PAR1 activation. However, although trypsin can cleave and activate PAR1, as shown in Vu *et al* (1991) the concentrations required (≥ 25 U/ml or 50 nM) are far in excess of those observed in the present studies on human coronary arteries to cause
20 endothelium-dependent relaxation (0.01 - 1 U/ml or 0.02 - 2 nM). The low potency of the human PAR2 tethered ligand sequence, SLIGKV-NH₂, and the lack of activity of the equivalent murine sequence, SLIGRL-NH₂, could initially be taken as evidence for the sole presence of PAR1 in human coronary arteries, with the specificity of this peptide being lost at high concentrations leading to "cross over"

- 63 -

activation of PAR1. The human PAR2 tethered ligand sequence, SLIGKVD-NH₂, however, does not activate PAR1 at concentrations up to 1 mM in human platelets (Blackhart *et al*, 1996) - far in excess of those used in this study. Furthermore, structure-activity studies have shown that PAR1 activating peptides lacking an
5 aromatic residue at position 2 (as is the case with SLIGKV-NH₂) are incapable of activating PAR1 in both transfected cell lines (Nystedt *et al*, 1995) and human platelets (Scarborough *et al*, 1992; Vassallo *et al*, 1992). Therefore, PAR1, and to a lesser extent PAR2, may exist in human coronary endothelial cells. Such a conclusion, however, is contrary to the present findings that heterologous
10 desensitisation was induced by either thrombin or trypsin.

Such evidence suggests a single receptor type. In porcine coronary arteries, which are known to express both PAR1 and PAR2 (Hwa *et al*, 1996), heterologous desensitisation was observed with high concentrations of trypsin, but only
15 homologous desensitisation occurred with thrombin (Hwa *et al*, 1996). Thus, while cross-desensitization and the poor sensitivity of SLIGKV-NH₂ and SLIGRL-NH₂ point to their involvement of a single receptor population, the ability of relatively low concentrations of trypsin to mediate relaxation similar to those observed with thrombin is inconsistent with the view that a 'typical' thrombin receptor is involved.

20

One explanation for these apparently disparate results is that human coronary artery endothelial cells possess an "atypical" thrombin receptor capable of activation by low concentrations of trypsin. For PAR1 and PAR3, low concentrations of thrombin cause rapid activation by means of a receptor-specific

- 64 -

recognition site for this enzyme, termed the hirudin-like binding domain (Liu, 1991; Vu *et al*, 1991). This thrombin-binding region is located in the extracellular amino-terminal, immediately distal to the Arg⁴¹-Ser⁴² cleavage point required for receptor activation, and allows close alignment of the thrombin catalytic site with this peptide bond (Vu *et al*, 1991). Therefore, these receptors are capable of targetting thrombin to their specific cleavage site, ensuring efficient receptor cleavage and rapid signal transduction prerequisites for efficient cellular responsiveness. Both the mouse and rat PAR2s are known to lack the hirudin-like thrombin binding domain (Saifeddine *et al*, 1996), and consequently are unresponsive to thrombin. However, these receptors most likely possess a similar amino-terminal recognition site for trypsin, since, like thrombin, trypsin causes high potency and rapid responses, most likely due to targeting of the enzyme to the PAR2 cleavage site.

15 The "atypical" thrombin receptor in the human coronary artery endothelial cell appears to be sensitively activated by both thrombin and trypsin *via* either a common or dual enzyme binding site(s). Further support for the existence of such a receptor is provided by the observation that SLIGKV-NH₂ is capable of inducing vasodilatation despite the lack of the critical aromatic residue at position 2.

20 Therefore, without wishing to be bound by any proposed theory, the inventors believe that the receptor responsible for endothelium-dependent relaxation of human coronary artery is a PAR1-like receptor, which has a modified amino-terminal exodomain comprising a trypsin binding domain and a modified tethered ligand binding region containing different pharmacophore specificities.

- 65 -

This study also shows that complete desensitization of responses to both thrombin and trypsin had only a small inhibitory effect on the responses of the arteries to SFLLRN-NH₂, which is contrary to earlier reports using pig coronary artery (Teshamarian, 1994; Hwa, 1996) and rat aorta (Holleberg *et al.*, 1996). However, differences in desensitization procedures between these previous studies and the present one might provide clues as to how PAR responsiveness is regulated following enzymic activation. In the present study, high concentrations of both thrombin and trypsin were used for 2 to 3 hours, followed by approximately 30 minutes recovery while enzyme washout and tissue contraction occurred. This resulted in complete loss of responsiveness to both thrombin and trypsin while retaining responsiveness to SFLLRN-NH₂. With a similar protocol in the pig coronary artery, homologous desensitization with thrombin and heterologous desensitization with trypsin were observed. However, in each case, responsiveness to SFLLRN-NH₂ and SLIGKV-NH₂ was maintained. In the study of Hwa *et al* (1996), a high enzyme concentration was used over a much shorter contact time (10 to 20 minutes), and importantly, the enzyme was not washed out. The results showed a loss of responses to SFLLRN-NH₂ after homologous desensitization with thrombin, and loss of both SFLLRN-NH₂ and SLIGKV-NH₂ responses following heterologous desensitization with trypsin.

20

The retention and loss of responses to the tethered ligand sequences following desensitization shown in the present studies and in that of Hwa *et al* (1996) may reflect the rates of internalization and recycling of PARs following enzymic activation. Both PAR1 and PAR2 are rapidly internalised upon enzymic activation,

stimulating the mobilisation of a pool of intact, pre-formed receptors which are rapidly (<30 minutes) inserted into the cell membrane (Bohm *et al*, 1996; Hein *et al*, 1994; Hoxie *et al*, 1993). The loss of subsequent enzyme-induced responses observed by Hwa *et al* (1996) using a rapid desensitization technique could be explained by the inability of the cell to replenish cell surface receptors from its intracellular reserve over this short period. With the prolonged desensitization technique used in this study, any reserves of intracellular receptors would probably have been depleted. Despite this, responses to SFLLRN-NH₂ were only minimally affected.

Therefore, it is proposed that, once activated, human endothelial cell PAR are internalised into early endosomes, as previously reported for human erythroleukemia cells (Hoxie *et al*, 1993), and are then returned to the membrane without their amino-terminal exodomain. Despite the absence of this exodomain they are able to respond to exogenously-applied tethered ligand sequences. This also indicates the presence of an endogenous activator which may act independently of receptor cleavage.

EXAMPLE 10

PAR-mediated relaxation in human bronchioles

Small (500 μ m) bronchioles were carefully dissected from discarded sections of human left lung which had been excised at surgery from two male lung cancer patients (49 and 63 years old, Royal Melbourne Hospital, Melbourne, Australia).

Dissection of these bronchioles required a fine-dissecting microscope and an assistant to continually flood the preparation with cold oxygenated Krebs solution to remove air bubbles and keep the tissue viable. Bronchioles approximately 2 mm in length were then mounted on 40 μ m diameter stainless wires in a Krebs solution-filled myograph chamber, as described for the mouse bronchus preparation above. Unlike the mouse bronchi, the human bronchiole preparation developed active force spontaneously after the initial stretch to 0.5g, then recovered partially as shown in Figures 24 and 25.

Like the mouse tissues, the human bronchioles were contracted to approximately 30-40% F_{max} with titrated cumulative concentrations of carbachol. Figures 24 and 25 show that both thrombin and trypsin caused activity dependent relaxation that was reversed by indomethacin. In contrast, only the PAR1-activating peptide SFLLRN-NH₂ (TRAP) relaxed the bronchioles. The PAR2-activating peptide, SLIGRL-NH₂ (PAR2- AP) appeared to cause some contraction, but this was most likely baseline drift.

This finding shows that thrombin and trypsin caused relaxation, but that only TRAP, not PAR2-AP, mimicked this activity. This is remarkably similar to the pattern of activity observed for PAR-mediated endothelium-dependent relaxation in the human isolated coronary artery in Example 5.

EXAMPLE 11**Cellular localization of PAR2 in the airway wall**

Before testing the hypothesis that airways epithelial PAR2 are bronchoprotective,
5 the inventors determined their cellular localisation with in the airway wall. Using an
antibody directed against the carboxyl terminal of mouse PAR2 and confocal
fluorescence microscopy. The inventors found specific PAR2 immunoreactivity
localised to epithelial cells, often focally within the cytoplasm, as well as to smooth
muscle cells and fibroblasts in the submucosa of the mouse bronchus. These
10 results are shown in Figure 26.

Fresh frozen, paraformaldehyde-fixed sections (14 μ M) of mouse bronchus were
incubated with a rabbit antiserum directed against the carboxy-terminal of mouse
PAR2 (CSVKTSY) at a dilution of 1:500 for 48h, washed with PBS and then
15 incubated with a biotinylated donkey anti-rabbit antiserum (Amersham) for 2 h,
washed again with PBS, and then labelled with FITC-conjugated streptavidin
(Amersham), all at room temperature. After a final wash in PBS, the sections were
mounted in buffered glycerol and viewed under a Biorad MRC1000 confocal
scanning laser system installed on an Olympus IMT2 microscope with a
20 krypton/argon laser. Visualisation of FITC was achieved using a 488 nm excitation
filter and a 522/535 nm emission filter. Images of 768 x 612 pixels were then
processed using Adobe Photoshop software.

The inventors demonstration that PAR2 immunoreactivity was often localised in
25 discrete cytoplasmic regions of airway epithelial cells supports the concept of rapid

- 69 -

turnover from intracellular stores ; which was demonstrated in Example 6.

Furthermore, the inventors were unable to demonstrate specific localisation of PAR2 mRNA in mouse bronchi using *in situ* hybridisation whilst readily detecting PAR2 mRNA in the same tissue *via* reverse-transcriptase-polymerase chain

5 reaction (RT-PCR). This discrepancy supports the idea that there are intracellular stores of receptors which are filled by translation of stable mRNA segments of low transcript number. Therefore, the capacity of airways epithelial cells *in situ* to rapidly replenish functional PAR2 following their enzymatic activation provides additional evidence that the epithelial PARs are involved in protection of the

10 bronchial wall during inflammation.

EXAMPLE 12

PAR2 in airway epithelium

15 Using an antibody directed against the carboxyl terminal of mouse PAR2 and confocal fluorescence microscopy, the inventors found specific PAR2 immunoreactivity localised to epithelial cells, often focally within the cytoplasm, as well as to smooth muscle cells and fibroblasts in the submucosa of the mouse bronchus (Figure 26). In functional studies, the mouse PAR2 tethered ligand

20 sequence, SLIGRL-NH₂ ([<400>2]; Nystedt *et al*, 1994) and trypsin each caused concentration-dependent, rapid onset and near-maximum relaxation of mouse bronchial rings contracted with the stable muscarinic agonist carbachol. These relaxations were abolished by either removal of the epithelium or inhibition of cyclooxygenase (Figures 1 & 26). For SLIGRL-NH₂ [<400>2] the sensitivity

25 (pEC₅₀, -log M) was 5.6 ± 0.1 and the maximum relaxation (R_{\max}) was $94 \pm 3\%$.

- 70 -

Similar concentration-dependent relaxations were obtained from the PAR1 tethered ligand sequence SFLLRN-NH₂ [$\langle 400 \rangle 1$]; Déry *et al*, 1988; λpEC_{50} , 5.6 ± 0.1 ; R_{max} , $76 \pm 11\%$) and thrombin. In contrast to PAR2 activation, removal of the epithelium or inhibition of cyclooxygenase unmasked smooth muscle contractions

5 to PAR1 activation with SFLLRN-NH₂ [$\langle 400 \rangle 1$] (Figures 1 & 26). Unlike SLIGRL-NH₂ [$\langle 400 \rangle 2$] (Blackhart *et al*, 1996) which is a specific activator of PAR2, SFLLRN-NH₂ [$\langle 400 \rangle 1$] can activate both PAR1 and PAR2. However, the inability of SLIGRL-NH₂ [$\langle 400 \rangle 2$] to contract epithelium-denuded or cyclooxygenase-blocked preparations of the mouse bronchi indicates that SFLLRN-NH₂ [$\langle 400 \rangle 1$]

10 causes smooth muscle contraction *via* activation of PAR1. It is clear that the relaxations observed in response to SLIGRL-NH₂ [$\langle 400 \rangle 2$] or low concentrations of trypsin were due to activation of epithelial PAR2 or an unidentified receptor with similar sensitivity to SLIGRL-NH₂ ($\langle 400 \rangle 2$) and trypsin. This is confirmed by the one observation that the responses to SLIGRL-NH₂ ($\langle 400 \rangle 1$) were abolished by

15 prior desensitisation to trypsin but were unaffected by thrombin desensitisation whilst those to SFLLRN-NH₂ ($\langle 400 \rangle 1$) were abolished following desensitisation to both thrombin and trypsin.

Relaxations to SLIGRL-NH₂ [$\langle 400 \rangle 2$] and SFLLRN-NH₂ [$\langle 400 \rangle 1$] in the mouse

20 bronchi were not due to nitric oxide (NO) since they were unaffected by the NO synthase inhibitor, N^G-nitro-L-arginine (100 μ M) and the NO scavenger, oxyhaemoglobin (20 μ M; Figure 26). Therefore, a prostanoid rather than NO mediated the relaxations of both PARs. PGE₂ is a likely candidate, since it is the most prevalent prostanoid released from the airway epithelium and the inventors

25 found it to sensitively and powerfully relax mouse bronchi (pEC_{50} , 8.2 ± 0.1 ; R_{max} ,

100%, Figure 1).

Smaller, intrapulmonary airways are likely to contribute more than larger airways to resistance to flow in the lungs. Therefore, the inventors investigated the effects of PAR-activating peptides in first generation branches of the mouse main bronchi. The inventors observed similar indomethacin-sensitive relaxations to the PAR ligands in these preparations although the sensitivity and maximum relaxation to both SFLLRN-NH₂ [$<400>1$] (pEC_{50} , 5.5 ± 0.02 ; R_{max} , $58 \pm 10\%$) and SLIGRL-NH₂ [$<400>2$] (pEC_{50} , 5.1 ± 0.05 ; R_{max} , $58 \pm 4\%$) were significantly less ($P < 0.05$) than those in the main bronchi (Figure 26).

Since enzymatic activation of PARs is irreversible, rapid resensitisation mechanisms are critical for the maintenance of tissue responsiveness to PAR-activating proteases. Turnover of cloned PAR1 expressed in selected cell lines has been shown to be rapid and dependent on both *de novo* synthesis of new protein as well as trafficking of performed receptors from intracellular pools (Dery *et al*, 1998; Bohm *et al*, 1996). The data generated herein show that in the mouse bronchi, PAR2-mediated relaxations returned after 45 min following desensitisation to trypsin (Figure 11b). This recovery was abolished by the protein trafficking inhibitor, brefeldin A (10 μ M) or the translation inhibitor, cycloheximide (70 μ M; Figure 11b). These findings, together with the demonstration here that PAR2 immunoreactivity was often localised in discrete cytoplasmic regions of airway epithelial cells (Figure 26), support the concept of rapid PAR2 turnover from intracellular stores in airway epithelium. Furthermore, the inventors were unable to demonstrate specific localisation of PAR2 mRNA in mouse bronchi using

- 72 -

in situ hybridisation whilst readily detecting PAR2 mRNA in the same tissue *via* reverse transcription-polymerase chain reaction. The apparent discrepancy between these findings could be explained by the immunohistochemical demonstration of intracellular stores of PAR2 (Figure 26) which are continually

5 replenished by translation of stable message of low transcript number. Thus, the capacity of airway epithelial cells *in situ* to rapidly recover their sensitivity to PAR2 agonists following receptor desensitisation supports a role for epithelial PAR2 in bronchoprotection.

10 In addition to the mouse, the inventors also observed PAR-mediated bronchorelaxation in the airways of other species. Thus, SLIGRL-NH₂ [$<400>2$] caused epithelium-dependent and indomethacin-sensitive relaxations in rat isolated bronchi (pEC₅₀, 5.5 \pm 0.1; R_{max}, 56 \pm 5%) and bronchioles (pEC₅₀, 5.1 \pm 0.1; R_{max}, 67 \pm 5%) and similar potency (pEC₅₀, 5.4 \pm 0.2), epithelium-dependent
15 relaxation in the guinea-pig isolated bronchi but with a significantly (P<0.05) lower R_{max} (31 \pm 5%) than those in both rat and mouse bronchi. Also, from experiments (n=4), the inventors observed PAR2-mediated relaxations in human intrapulmonary airways which, although weak by comparison with those in mice, were blocked by indomethacin.

20

Importantly, the inventors have demonstrated here that SLIGRL-NH₂ [$<400>2$] is a highly effective inhibitor of bronchoconstriction *in vivo*. Thus, a 30 sec exposure to an aerosol of a 0.1 mg/ml solution of SLIGRL-NH₂ [$<400>2$], but not the scrambled peptide sequence LSIGRL-NH₂ [$<400>4$] caused inhibition (50-70%) of 5-

25 hydroxytryptamine (5-HT)-induced changes in airway resistance (R_L) and dynamic

- 73 -

compliance (C_{dyn}) in anaesthetised rats (Figure 11b). This effect of SLIGRL-NH₂ [400>2] could be functionally antagonised by higher doses of 5-HT.

It is clear from the data presented herein that the PAR-mediated
5 bronchorelaxation described herein is cyclooxygenase-dependent. PGE₂ is the likely prostanoid involved since it is the only cyclooxygenase product released by airway epithelial cells capable of inducing potent bronchorelaxation. Also, substance P, another substance which induces epithelium-dependent bronchorelaxation, has been shown to mediate this response in the rat bronchi *via*
10 release of PGE₂ from the epithelium. PGE₂ exerts other bronchoprotective actions in humans at concentrations well below those required for bronchodilatation. These include inhibition of cholinergic neurotransmission, lung mast cell activation, eosinophil chemotaxis, IL-2 production by T lymphocytes and IL-4-induced IgE production by B lymphocytes. Furthermore, PGE₂ synthesised by human airway
15 epithelium probably contributes to refractoriness to histamine challenge in humans and exercise-induced asthma. Also, inhalation of PGE₂ in allergic asthmatics not only prevents the early phase of the response to allergen challenge but the late phase as well. Therefore, although inhalation of PGE₂ causes acute cough in man, stimulation of endogenous PGE₂ release by PAR2 may place crucial roles in
20 airway defence.

The studies presented herein assign functionality for PAR2 and PAR2 in the airways. Also, they show that PAR2 activation results in powerful bronchodilatation *in vivo* and epithelium-dependent bronchial relaxation *in vitro*
25 with no evidence for direct contraction. Therefore, airway epithelial PAR2 is

- 74 -

bronchoprotective. However, because PAR2 is also expressed in the subepithelium, particularly on smooth muscle cells, the inventors propose a dual compartment model for the role of PAR2 in the airways. In this model the barrier function of the epithelium separates epithelial cells (compartment 1) from the
5 underlying tissues in compartment 2. Also, epithelial and subepithelial PAR2 are differentially regulated by specific tryptic enzymes released preferentially in each compartment - epithelial trypsin for compartment 1 and mast cell tryptase for compartment 2. The inventors propose that trypsin is the endogenous activator of epithelial PAR2 is supported by the demonstration here that trypsin(ogen) is co-
10 localised with PAR2 in human airway epithelium. In addition, trypsin is regulated by α_1 -antitrypsin in the lungs whereas there are no known inhibitors of mast cell tryptase. Therefore, the model predicts that epithelial PAR2 normally override any proinflammatory effects of PAR2 activation in compartment 2 and that disruption of the epithelial barrier compromises the normal balance between the two
15 compartments.

This study indicates that epithelial PAR2 causes powerful bronchorelaxation *in vitro* and that their activation *in vivo* suppresses bronchoconstriction. Therefore, activation of PAR2 initiates important paracrine protection in the airways by
20 functionally antagonising elevated airway tone. If PGE₂ is the mediator of this effect, then airway epithelial PAR2 have the potential to initiate other paracrine protective responses as well as autocrine protective effects within the epithelium. As such, these receptors offer scope for new therapies for diseases like asthma and bronchitis. This is supported by the demonstration that inhalation of PGE₂ in
25 mild asthmatics markedly inhibited allergen-induced airway responses

- 75 -

(constriction) and airway inflammation. The present invention provides a mechanism of activating the PGE₂-mediated bronchoprotection system.

EXAMPLE 13

5 PAR mediated relaxation in mouse bronchioles

In addition to the findings in mouse bronchi, shown in the earlier Examples, indomethacin-sensitive relaxations to both the PAR1- and PAR2-activating peptides were also observed in first branches of the main bronchi of the mouse, which the
10 inventors have termed bronchioles. However, the sensitivity and maximum relaxation to SFLLRN-NH₂ (pEC₅₀ 5.5 ± 0.02; R_{max} 58 ± 10%) and SLIGRL-NH₂ (pEC₅₀ 5.1 ± 0.05; R_{max} 58 ± 4%) were significantly less (P<0.05) than those shown in Figure 27 for the main bronchi. Similar responses to SLIGRL-NH₂ were observed in other species. Thus, SLIGRL-NH₂ caused indomethacin-sensitive relaxations in
15 rat bronchi (pEC₅₀ 5.5 ± 0.1; R_{max} 56 ± 5%) and bronchioles (pEC₅₀ 5.1 ± 0.01; R_{max} 67 ± 5%) and similar potency (pEC₅₀ 5.4 ± 0.2%) epithelium-dependent relaxation in the guinea-pig but with significantly (P<0.05) lower efficacy (R_{max} 31 ± 5%) than in both rat and mouse bronchi. Furthermore, in preliminary experiments, the inventors observed PAR2mediated relaxation in human bronchi (n=4), which in one case was
20 blocked by indomethacin. The similar potencies for SLIGRL-NH₂ in mice, rats and guinea-pigs indicate expression of a similar receptor, whilst the different efficacies suggest either different receptor numbers or coupling between species. The rank order of efficacies for SLIGRL-NH₂, mouse > rat > guinea-pig, however, contrasts with the severity of symptoms in allergic models of asthma. For example, mice
25 show resistance to immunological challenge including only a small degree of airway

- 76 -

hyperreactivity (AR) compared with rats and guinea-pigs, the latter of which show characteristic high levels of A4¹⁶ and may die when exposed to similar immunological challenges. One reason why mice appear relatively asymptomatic when used in immunological models of asthma may in part be due to a higher
5 relative effectiveness of their PAR2-dependent bronchoprotective mechanism.

The mouse PAR2 tethered ligand sequence, SLIGRL-NH₂ (Nystedt *et al*, 1994) and trypsin each caused concentration-, epithelium- and cyclooxygenase-dependent, rapid onset and near-maximum relaxations of mouse bronchial rings contracted with
10 the stable muscarinic agonist carbachol, as shown in Figures 26b and c and Figure 27. For SLIGRL-NH₂ the sensitivity (pEC₅₀, -log M) was 5.6 ± 0.1 and the maximum relaxation (R_{max}) was $94 \pm 3\%$. Similar concentration-dependent relaxations were also obtained to the PAR1 tethered ligand sequence SFLLRN-NH₂ (Dery *et al*, 1998) [pEC₅₀ 5.6 ± 0.1 ; R_{max} $76 \pm 11\%$] and thrombin. In contrast to
15 PAR2, however, both removal of the epithelium and inhibition of cyclooxygenase with either indomethacin or aspirin unmasked direct smooth muscle contractions to PAR1 activation, as shown in Figures 26 and 27. Neither of the relaxations to SLIGRL-NH₂ and SFLLRN-NH₂ was due to nitric oxide (NO), since they were completely unaffected by the NO synthase inhibitor, N^G-nitro-L-arginine (100 μM)
20 either alone, or in combination with the NO scavenger, oxyhaemoglobin (20 μM), a combination of NO inhibitors which abolishes all NO release from vascular endothelial cells *in situ* (Drummond and Cocks, 1996; Kemp and Cocks, 1997). Therefore, these results indicate that a prostanoid released from the epithelium mediated the relaxations to both PARs. PGE₂ is a likely candidate, since it is the
25 most prevalent prostanoid released from the airway epithelium, as shown in Figure

- 77 -

26, and the inventors found it to be a potent bronchodilator in this tissue, causing 100% relaxation with a pEC₅₀ of 8.2 ± 0.1 (n=6).

The relaxations to SLIGRL-NH₂ and SFLLRN-NH₂ in the mouse bronchi were likely
5 to have been due to activation of separate receptors, since those to SLIGRL-NH₂ were abolished by prior desensitisation to trypsin but not thrombin whilst those to SFLLRN-NH₂ were inhibited by both thrombin and trypsin, as shown in Figure 28. Also, desensitisation with SLIGRL-NH₂ blocked the response to trypsin. This pattern
10 of activity agrees with previous reports showing that thrombin only activates PAR1 while higher concentrations of trypsin can activate both PAR2 and PAR1 (Vu *et al*, 1991 ; Molino *et al*, 1997).

EXAMPLE 14

Lung inflammation studies

15

Mice were challenged with bacterial lipopolysaccharide (LPS; 10 µg/mouse) *via* intranasal administration under light halothane anaesthesia. Prior to this challenge, mice were treated with SLIGRL-NH₂ (2 mg/kg or 20 mg/kg) or saline (control) *via* the same route of administration.

20

Three hours after receiving LPS, the mice were killed *via* an intraperitoneal injection of sodium pentobarbitone and the lungs were cannulated and lavaged with 4 x 0.5 ml washes of phosphate buffered saline. The total number of cells retrieved by this procedure was determined with a haemocytometer. Differential counts of individual
25 cell types were performed on cytopsin preparations of the lavage fluid, stained with

- 78 -

the conventional May-Grünwald/Giemsa blood stain. The total number of neutrophils in each sample was then calculated from the proportion of neutrophils in the cytospin preparations, as a proportion of the total number of cells retrieved. In animals which received neither LPS or SLIGRL-NH₂, very few neutrophils were
5 observed.

Figure 36 shows group data for n=7 controls, n=3 at 2mg/kg SLIGRL and n=6 at 20mg/kg SLIGRL. Clearly prior treatment with SLIGRL causes a dose-dependent inhibition of the increase of neutrophil infiltration into the lungs in response to LPS.
10

These data further show that activation of epithelial PAR2 evoke a generalised bronchoprotective response in the airways.

EXAMPLE 15

15 **Ussing methods for determination of PAR-induced
 changes in airways epithelial ion transport.**

Methods

Mice were killed by a lethal overdose of sodium pentobarbitone and the tracheae
20 rapidly excised. The trachea was opened longitudinally through the ventral cartilage rings to make a flat sheet. Each sheet of trachea was mounted between two perspex chambers so that the mucosal (luminal) and submucosal and bathed with warmed, oxygenated Krebs' solution, independently on each side. Electrodes in the chambers allowed recordings of transepithelial potential difference using an
25 amplifier. The tissue was voltage clamped at 0 mV by passing a current from the

- 79 -

amplifier *via* another set of electrodes in the chambers. The amount of current required to maintain voltage at 0 mV is defined as the short circuit current (I_{sc}) and is conventionally used as a measure of all ionic fluxes across the preparation.

- 5 Human airways were obtained from discarded sections of lungs of patients undergoing lobectomy operations at the Royal Melbourne Hospital, Melbourne, Australia usually for lung cancer. The dissection and set up were as described above for the mouse trachea.
- 10 After an equilibration time of 30 min, compounds for testing and drugs to elucidate the mechanism of any changes in I_{sc} to the test compounds were added to either side of the tracheal epithelium (ie to either bath). Compounds used for increasing I_{sc} were PGE₂, adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP) and the PAR1-, PAR2- and PAR4-activating peptides, SFLLRN and SLIGRL and
- 15 GYPGQY, respectively. These stimulants were added cumulatively with controls for any time-dependent tachyphylaxis.

Results

Mouse trachea

20

Figure 30 shows typical original traces of the increases in I_{sc} in response to luminally-applied ATP, SLIGRL and PGE₂. For all three cases, each concentration of activator caused a rapid initial rise in I_{sc} usually followed by some degree of recovery until a steady plateau was reached. The group data for these and other

25 activators is depicted in Figure 31. Figure 33 provides digitised traces of original

- 80 -

chart recordings showing the effects of inhibitors of two distinct chloride channels on changes in *I*_{sc} to single, submaximal concentrations of ATP, PGE₂ and SLIGRL. The drugs used were glibenclamide (G), an inhibitor of the cystic fibrosis transmembrane regulator (CFTR; Schultz *et al*, 1999) and DIDS, an inhibitor of calcium-activated chloride channels (ClCa; Gruber *et al*, 1999). From the group data for these experiments shown in Figure 33, it can readily be seen that whilst most of the chloride conductance to SLIGRL was due to the CFTR channel, a substantial amount remained due to ClCa. These increases in *I*_{sc} to SLIGRL, ATP and PGE₂ in the mouse airways were unaffected by the cyclooxygenase inhibitor, indomethacin.

Human bronchi

Figure 34 depicts increases in *I*_{sc} to the PAR2- and PAR1-activating peptides, SLIGKV and SFLLRN respectively in the epithelium of a section of human intralobular bronchus. Prior to addition of the drugs shown, the preparation was incubated with amiloride, because secretory responses cannot be observed in human tissues unless sodium channels are inhibited by this drug. The maximum response elicited by the phosphodiesterase inhibitor, isobutylmethylxanthine (IBMX) is included. Note that the relatively poor response to the human PAR2-activating peptide, SLIGKV, is in keeping with other data presented herein for PAR2 function (epithelium-dependent smooth muscle relaxation) and the apparent low level of expression of the receptor as determined by immunohistochemistry.

Discussion

The finding that all three PAR-activating peptides increase chloride conductance in mouse airways and the preliminary data in human airways which shows that
5 activation of PAR2 also increase I_{sc} , further indicates that epithelial PAR2 in the airways (and most likely epithelial PAR1 and PAR4) are bronchoprotective. An increase in chloride secretion encourages water to follow and maintain the sol layer beneath the mucous layer (Boucher, 1999). Secretion of mucous from mucous goblet cells is also stimulated submucosally by PGE_2 (see Figure 1) as is
10 vasodilatation which enables fluid to follow the movement of ions. The finding that the increases in I_{sc} to PAR2 and ATP did not involve a cyclooxygenase product (ie PGE_2) indicates that these receptors are directly linked to the two chloride channels underlying I_{sc} changes as well as to the production of PGE_2 and its release into the submucosal compartment to orchestrate the many other anti-inflammatory
15 mechanisms already alluded to (see Figure 35).

An additional finding from this study may have important implications for treatment of people with cystic fibrosis (CF). These patients lack the CFTR and as a consequence the mucous layer in the airways becomes sticky due to the reduction
20 in the efficiency of production of the layer of fluid normally maintained by the conductance of chloride through the CFTR (Boucher, 1999). Because CF patients cannot move airway mucous and its entrapped pathogens, their lungs become persistently inflamed by bacterial infection, resulting ultimately premature (<30 yr) death. Activators of the alternative $ClCa$ particularly by ATP and UTP have recently
25 attracted much attention as a possible new therapeutic approach to improving the

- 82 -

lung function of CF patients (eg Olivier *et al*, 1996) since this channel is present in CF patients. The present finding that PAR2 activators can also activate the ClCa are novel and also potentially important given that this effect is concomitant with generalised bronchoprotection indirectly *via* the release of PGE₂. The fact that the PAR-activating peptides were not as potent or efficacious as ATP may be related to endogenous peptidases that cleave the peptide PAR agonists. Stable peptides or non-peptide PAR-activators would not be subject to this process.

EXAMPLE 16

10 **Effects of PAR agonists on monkey airways**

Figure 37 is a representation of digitised original chart recordings showing the smooth muscle relaxing effects of PAR1 and PAR2 peptide activators, SLIGKV and SFLLRN respectively and the PAR activating enzymes, thrombin (PAR1 selective) and trypsin (PAR2 selective) in isolated ring segments of monkey small bronchi. 15
Traces are characteristic of similar tissues taken from four separate animals (two pigtail macaques; two cynamologus). The experimental details are similar to those for the mouse isolated bronchi. Briefly, approximately 2 mm long rings of small bronchi were mounted on wire hooks. In each trace, half log concentrations are not 20 depicted for clarity. In some cases PGE₂ and isoprenaline (iso) were added to (1) show that these tissues were responsive to PGE₂ and (2) to obtain maximum tissue relaxation.

EXAMPLE 17**Effects of PAR agonists on rat airways**

Figure 38 provides cumulative concentration-response curves to the PAR1, PAR2
5 and PAR4-activating peptides, SFLLRN, SLIGRL and GYPGKF and the PAR-
activating enzymes, thrombin and trypsin in isolated rat trachea (a, d) bronchi (b, e)
and first bronchi (c, f). Values are expressed as percentage relaxation or
contraction from carbachol-induced contraction (mean \pm s.e. mean %, $n=6-12$).
Confocal microscopic imaging was used to confirm the immunohistochemical
10 localisation of PAR2 in rat trachea, bronchi and intrapulmonary bronchi. Co-
localisation of PAR2 immunofluorescence with two separate PAR2 antibodies,
PAR2-C antibody (green) and PAR2-N antibody (red) superimposed images show
as yellow staining.

15

EXAMPLE 18**PAR-Like Receptor**

Activation of PAR-like receptor results in endothelium-dependent, NO-mediated
relaxation of contracted human coronary arteries *in vitro*. This receptor either has a
20 common, low stringency "hirudin-like" thrombin binding domain, or other binding
domains such that serine proteases other than thrombin (eg. trypsin) can sensitively
activate it. This receptor also appears to be recycled *via* a mechanism whereby
cleaved (activated) receptors are returned to the membrane, and are able to
respond to agonists acting independently of receptor cleavage. The
25 pathophysiological roles of endothelial cell PARs in human coronary arteries are

unknown, although one possibility is that by inducing a vasodilator response, these receptors may limit the degree of thrombosis following plaque invasion by mast cells, as this process is known to be associated with release of proteases such as the trypsin like enzyme, tryptase (Kovanan *et al*, 1995). The non-selectivity to
5 activation of this novel PAR receptor by thrombin and trypsin may also extend to other proteases.

The studies described herein have identified functional PAR1 and PAR2 in the bronchi of mouse, rat, domestic pigs and guinea-pigs which, when activated by
10 specific proteases, thrombin and trypsin or the human PAR1 and mouse PAR2 tethered ligand sequences, SFLLRN-NH₂ and SLIGRL-NH₂ respectively, cause profound relaxation of bronchial muscle. PAR2, and most likely PAR1 are located in the epithelium, and when activated, mediate smooth muscle relaxation *via* the release of endogenous prostaglandin (PG), most likely PGE₂. This relaxation was
15 as rapid and complete as that for isoprenaline, the clinically most efficacious and rapidly acting beta-adrenoceptor agonist bronchodilator currently available.

The inventors have demonstrated for the first time that two types of PAR receptors, PAR1 and PAR2, are located on bronchial epithelial cells. Without wishing to be
20 limited by any proposed mechanism, the inventors postulate that activation of these receptors mediates relaxation of the airway by stimulating release of PG, most likely PGE₂, an endogenous local hormone. This relaxation is as efficient and rapid as that elicited by the most effective known bronchodilator drugs, the beta-2-adrenoceptor agonists, exemplified herein by isoprenaline. Therefore, the findings

described herein demonstrate that activation of PAR stimulates activation of a potent and highly efficient protective mechanism that operates to keep the airways open. Furthermore, the PGE₂ released by PAR activation may have an important role in protecting airway tissue from pathological change by regulating tissue responses to injury and regulating mucosal immunity.

The studies disclosed herein are not only the first to describe functionality for PAR2 and PAR1 in the airways, but they also show that PAR2 activation results in powerful epithelium-dependent bronchodilatation with no evidence for direct contraction, even though PAR2 was also localised on smooth muscle cells. As described herein the mouse, PAR2 is also expressed in both the epithelium and smooth muscle cells of human airways.

This dual localisation to PAR2 to the mucosal and submucosal layers of the airways is important, however, since it reconciles the inventors' proposal that epithelial PAR2 is anti-inflammatory, with the current dogma that like PAR1, PAR2 is pro-inflammatory (Déry *et al*, 1998), possibly being activated by mast cell-tryptase (Molino *et al*, 1997). Thus, the inventors propose a dual compartment model for the role of PAR2 in the air ways. In this model, anti-inflammatory epithelial PAR2 (compartment 1) normally override any pro-inflammatory effects of smooth muscle and perhaps fibroblast PAR2 (compartment 2) activated by mast cell tryptase, since PGE, potently inhibits mast cell activation. It is interesting to note that trypsin has been localised in epithelial cells of normal human airways. The inventors confirmed this finding and furthermore localised specific trypsinogen immunofluorescence to

Clara cells in human bronchi. Therefore, in this model, epithelial and smooth muscle PAR2 may be differentially regulated by specific tryptic enzymes released preferentially in each compartment.

5 Based on these findings and the vasodilator effects of PARs in blood vessels, it appears that PAR activation is a general protective mechanism relevant, but not limited, to epithelia of bronchi and vessels, mucosal surfaces and joint connective tissues. Defects in this system may be important determinants of disease susceptibility and severity. Since PARs are activated by tissue injury and proteases
10 are released both during innate and acquired immune responses, this invention has broad application to numerous disease states where deficient intrinsic protection from injury contributes to disease pathogenesis and/or severity. Therefore, the present invention has wide application in the design of diagnostic and therapeutic strategies for managing these conditions.

15

The invention makes possible new treatments for many, if not most, inflammation-related diseases of the airways. It may also apply to atherosclerosis in blood vessels, as well as to similar inflammation-mediated diseases of other muscle-lined tubes in the body, such as the bile duct, urogenital tract etc). The
20 mechanism of relaxation of the PAR of the present invention offers scope for avoiding the limitations of beta-2 therapy. Treatment of inflammation-induced insufficiency in airways, for example in asthma, *via* this new pathway involves activation of a naturally-occurring system. Thus, it offers the prospect of being able to cure these diseases with gene therapy techniques, particularly given the easy

route of access for adding the extra copies of the PAR2 gene. It also offers a possible solution to the long-standing problem as to why the airways of healthy individuals are protected from obstruction, whereas those of asthmatics are not protected. Furthermore, the need for vascular endothelial and airway epithelial cells to replace PAR2 quickly implies that they serve a protective function, rather than causing cell damage as previously believed, due to the potentially deleterious effects of mast cell-derived tryptase in preventing or treating infection.

The findings described herein not only demonstrate that blood vessels and airways are similar in that their inner lining cells possess powerful smooth muscle relaxing mechanisms, but also suggest that PARs may orchestrate a more general endogenous protective tissue response to inflammatory challenge and disease, which includes regulation of smooth muscle contractility, inflammatory cell migration and function, neural activity and tissue remodelling. PARs are ideally configured for such a role. They are in effect "caged", theoretically lying dormant until activated by specific proteases, many of which are known to be involved in airway immune and inflammatory responses, as depicted in Figure 12.

Furthermore, following activation they are inactivated by rapid internalisation, which then signals equally rapid replenishment of new receptors from intracellular pools and *de novo* protein synthesis from stably expressed mRNA. Finally, the location of PARs to the epithelium is ideal for mediating such protease-dependent responses to airborne allergens, particularly suppression of contractility in the underlying smooth muscle, as shown in Figure 13.

Prostaglandin E2 and asthma

Although the potentially beneficial effects of PGE₂ as a relaxant agent, modulator of immune responses and regulator of tissue response to injury have been appreciated
5 for some time, it has not proven possible to deliver PGE₂ or mimetics safely to the airways (Nizankowska *et al*, 1985; Daniell *et al.*, 1994 and Melillo *et al*, 1994). The major limitation to exploiting the benefits of PGE₂ has been that exogenous PGE₂:
(i) potently activates sensory nerves in the airways, causing severe coughing (Costello *et al*, 1985; Stone *et al*, 1992; and
10 (ii) dysregulates airway mucosal blood flow (Laitinen *et al*, 1987).

Regardless of these limitations for exogenously applied PGE₂, PGE₂ has several actions likely to be of considerable benefit in asthma. PGE₂ suppresses cholinergic bronchoconstriction reflexes at the level of acetylcholine release. PGE₂ potently
15 inhibits activation of macrophages and lymphocytes, both of which are implicated in the pathogenesis of chronic human asthma. PGE₂ also suppresses the formation of new tissue matrix by inhibiting activation of mesenchymal cells such as airway fibroblasts. It is of considerable interest that asthmatics may die from catastrophic bronchospasm if cyclooxygenase is inhibited. There is also a large body of evidence
20 that PGE₂ can be generated by the normal epithelium of airways, as well as by macrophages and airways cartilage. PGE₂ administered by aerosol protects asthmatics from exercise-induced asthma and from induced mediator-induced bronchospasm (eg with methacholine), although it is tolerated very poorly.

25 Therefore, the present invention represents a novel method to harness the

- 89 -

therapeutic potential of PGE₂ by causing its endogenous release within tissues.

In conclusion, and without wishing to be bound by any proposed mechanisms for the observed advantages, it appears that PARs mediate powerful epithelium-

5 dependent bronchodilatation, most likely *via* PGE₂, which offers scope for new and effective therapies for airway inflammatory diseases like asthma and bronchitis.

Also, individuals susceptible to inappropriate loss or down-regulation of the PAR2 protective defence would be more likely to develop disease or diseases of increased severity; this finding provides the basis for new diagnostic and prognostic methods.

10

Table 3 provides a summary of some of the characteristics of PAR1-PAR4 the four cloned PARs. The schema shown Figure 1 depicts a common PAR weaving in and out of the plasma membrane of a cell. Cell signalling is initiated following G-protein coupling. Note that the chromosomal location given in Table 3 is for human PARs.

15

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described.

It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions

20 and compounds referred to or indicated in this specification, individually or

collectively, and any and all combinations of any two or more of said steps or features.

TABLE 3

	PAR1	PAR2	PAR3	PAR4
Selective enzyme activator	Thrombin	Trypsin	Thrombin	Thrombin and trypsin
Chromosome	5q13	5q13	5q13	19p12
Other enzyme activators	Trypsin Mast cell tryptase	Mast cell tryptase		
Cleavage site (human)	-Arg ⁴¹ -Ser ⁴² -	-Arg ³⁴ -Ser ³⁵ -	-Lys ³⁸ -Thr ³⁹ -	-Arg ⁴⁷ -Gly ⁴⁸ -
Hirudin-like alignment site	Yes	No	Yes	No
Tethered ligand sequences	SFLLRN(h) TFRIFD(x) SFLLRN (m,r)	SLIGRL(m,r) SLIGKV(h)	TFRGAP(h) SFNGGP(m)	GYPGKF(m) GYPGQV(h)
Activity of synthetic tethered ligand sequences	Active	Active	Inactive	Active
G-protein coupling	G $\alpha_{q/11}$ G α_i G α_0 G α_{12} G α_{13}	G α_q G α_0	Unknown	Unknown

Key: h, human; m, mouse; r, rat; x, *Xenopus*.

BIBLIOGRAPHY

- Atkinson, J. B., *et al.* *Hum. Pathol.* 25: 154-159, 1994.
- Barnes, P. J., *et al.* *Eur. Respir. J.* 9: 636-642, 1996a.
- 5 Barnes, P. J., *Br. J. Clin. Pharmacol.* 42: 3-10, 1996b.
- Barnes, P.J., *et al.* *Am. J. Respir. Crit. Care Med.* 153: 23-25, 1996c.
- Blackhart, B.D., *et al.* *J. Biol. Chem.* 271: 16466-16471, 1996.
- Bohm, S. K., *et al.* *Biochem. J.* 314: 1009-1016, 1996a.
- Bohm, S. K., *et al.* *J. Biol. Chem.* 271: 22003-22016, 1996b.
- 10 Boucher, RC *J. Physiol.*, 516: 631-638., 1999.
- Caughey, G. H., *Am. J. Respir. Mol. Biol.* 16: 621-628, 1997.
- Caughey, G. H., *Am. J. Respir. Crit. Care Med.* 150: 138-142, 1994.
- Chester, A.H., O'neil, G. S., Tadjkarimi, S., Palmer, R.M.J., Moncada, S. and Yacoub, M.H. *Int. J. Cardiol.* 29: 305-309, 1990.
- 15 Costello, J.F., Dunlop, L.S. and Gardiner, P.J. *Br-J-Clin-Pharmacol.*, 20: 355-9, 1985.
- Coughlin, S. R., *et al.* *J. Clin. Invest.* 89: 351-355, 1992.
- Daniel, E.E., Abela, A.P., Janssen, L.J. and O'Byrne, P.M. *Can-J-Physiol-Pharmacol.* 70: 624-34, 1992.
- 20 De Caterina, R., *et al.* *Pharmacol. Res.* 27: 1-19, 1993.
- Dennington, P. M., *et al.* *Clin. Exp. Pharmacol. Physiol.* 21: 349-358, 1994.
- Déry, O., *et al.* *Am. J. Physiol.* 274: 1429-1452, 1998.
- Drummond, G.R. and Cocks T.M. *Br. J. Pharmacol.*, L17: 1035-1040, 1996.
- Fager G., *Circ. Res.* 77: 645-650, 1995.
- 25 Garland, C. J. *et al.* *Trends Pharmacol. Sci.* 16: 23-30, 1995.

- Glusa, E. and Markwardt, F. *Biomed. Biochem. Acta*, 47: 623-630, 1988.
- Grubb, BR & Boucher, RC. *Physiol. Rev.*, 79 (suppl. 1): S193-S214, 1999.
- Gruber, AD, Schreur, KD, Ji, H-L, Fuller, CM & Pauli, BU. *Am. J. Physiol.*, 276: C1261-C1270, 1999.
- 5 Hamilton, J. R. *et al. Circ. Res.* 82: 1306-1311, 1998.
- Hoxie, J. A. *et al, J. Biol. Chem.* 268:13756-13763, 1993.
- Hwa, J. J. *et al, Circ. Res.* 78: 581-588, 1996.
- Ishihara, H., *et al, Nature* 386: 502-506, 1997.
- Kemp, B.K. and Cocks, T.: *d. Br. J. Pharmacol.*, 120: 757-762, 1997.
- 10 Kahn, M. L. *et al, Nature* 394: 690-694, 1998.
- Kemp, B. K. *et al. Br. J. Pharmacol.* 120: 757-762, 1997.
- Koshikawa, N., *et al, FEBS Letters* 409: 442-448, 1997.
- Kovanen, P. T. *et al, Circulation* 92: 1084-1088, 1995.
- Kruse, H. J. *et al, Am. J. Physiol.* 268: 36-44, 1995.
- 15 Laitinen, L.A., Laitinen, A. and Widdicombe, J. *Am-Rev-Respir-Dis.*, 135: S67-70, 1987.
- Liu, L.W., Vu, T.-K.H., Esmon, C.T. and Coughlin, S.R. *J. Biol. Chem.*, 266: 16977, 16980, 1991.
- Mari, B., *et al, FASEB J.* 10: 309-316, 1995.
- 20 Molino M., *et al, The Journal of Biological Chemistry* 272: 4043-4049, 1997.
- Moncada, S., *et al, Pharmacol. Rev.* 4: 109-142, 1991.
- Muramatsu, I., *et al, Can. J. Physiol. Pharmacol.* 70: 996-1003, 1992.
- Nelken, N. A., *et al, J. Clin. Invest.* 90: 1614-1621, 1992.
- Nizankowska, E., Sheridan, A.Q., Maile, M H., Cross, J., Nizankowski, R.,
- 25 Prochowsk a, K. and Szczeklik, A. *Prostaglandins*, 29: 349-62, 1985.

- Ngaiza, J. R., *et al*, *Biochem. Biophys. Res. Comm.* 179: 1656-1661, 1991.
- Nystedt, S., *et al*, *Proc. Natl. Acad. Sci. USA* 91: 9208-9212, 1994.
- Nystedt, S., *et al*. *Proc. Natl. Acad. Sci. USA* 91: 9208-9212, 1994.
- 5 Olivier, KN, Bennet, WD, Hohneker, KW, Zeman, KL, Edwards, LJ, Boucher, RC, Knowles, MR. *Am. J. Respir. Crit. Care Med.*, 154: 217-223, 1996.
- Saifeddine, M., *et al*. *Br. J. Pharmacol.* 118: 521-530, 1996.
- Schwarze, S. R. *et al*. *Nature* 285: 1569-1572, 1999.
- 10 Stork, A.P. and Cocks, T.M. *Br. J. Pharmacol.*, L13: 1099-1104, 1994b
- Stork, A.P, and Cocks, T.] 1. *Br. J. Pharmacol.*, L13: 1093-1098, 1994a.
- Stork, A.P. and Cocks, T.] d. *Br. J. Pharmacol.*, L13: 1099-1104, 1994b.
- Scarborough, R.M., Naughton, M.A., Teng, W., Hung, D.T., Rose, J., Vu, T.-K.H., Wheaton, V.I., Turek, C.W. and Coughlin, S.R. *J. Biol. Chem.*, 15 267: 3146-13149, 1992.
- Schultz, BD, Singh, AK, Devor, DC & Bridges, RJ. *Physiol. Rev.*, 79 (suppl. 1): S109-S144, 1999
- Tesfamariam, B., *et al*, *Am. J. Physiol.* 265: 1744-1749, 1993.
- Tesfamariam, B. *Am. J. Physiol.*, 1994 267 H1962-H1967.
- 20 Vassallo, R.R.J., Kieber- Emmons, T., Cichowski, K. and Brass, L.F. *J. Biol. Chem*, 267 6081-6085, 1992.
- Vu, T-K. H. *et al*, *Cell* 646: 1057-1068, 1991.
- White, R.P., Shimazaki, Y. and Robertson, J.T. *Blood Vessels*, 21: 12-22, 1984.
- 25 Xu *et al*, *Proc. Natl. Acad. Sci. USA* 95: 6642-6646, 1998.

Yamada, T., *et al.* *Surgery* 119: 494-497, 1996.

Yasuoka, S., *et al.* *Am. J. Respir. Cell Mol. Biol.* 16: 300-308, 1997.

- 95 -

CLAIMS:

1. A method for the prophylaxis or treatment of an airway disease condition in an animal, said method comprising administering to said animal, an effective amount of an agent capable of activating an airway epithelium protease activated receptor (PAR) for a time and under conditions sufficient for activation of said PAR to occur wherein the activated PAR stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation.
2. A method according to claim 1 wherein the animal is a human.
3. A method according to claim 1 or 2 wherein the PAR is PAR1 or PAR2.
4. A method according to claim 3 wherein the PAR is PAR2.
5. A method according to claim 3 wherein the airway disease condition is asthma, bronchitis, hayfever, alveolitis, ciliary dyskinesia or pulmonary inflammation.


- 96 -

6. A method according to claim 3 wherein the agent is a peptide selected from <400>1, <400>2 and <400>3 or functional equivalents, homologues or derivatives thereof.
7. A method according to claim 6 wherein the peptide is modified to permit entry across an epithelial and/or subcutaneous layer.
8. A method according to claim 7 wherein the peptide is fused to penetratin.
9. A method according to claim 7 wherein the peptide is fused to TAT or a functional derivative or homologue thereof.
10. A composition useful for facilitating bronchoprotection said composition comprising an activator of a PAR in airway epithelium and one or more pharmaceutically acceptable carriers and/or diluents.
11. A composition according to claim 10 wherein the PAR is PAR1 or PAR2.

- 97 -


12. A composition according to claim 10 wherein the PAR is PAR2.
13. An isolated molecule comprising protease activated receptor (PAR) — activity wherein said molecule is isolatable from airway epithelium and upon activation, stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in humans and animals.
14. An isolated molecule according to claim 12 wherein the PAR molecule is PAR2.
15. A recombinant, synthetic or purified, naturally occurring molecule comprising protease activated receptor-2 (PAR2) activity wherein said molecule in its naturally occurring form is isolatable from airway epithelium and upon activation by a PAR2 activating peptide, stimulates, induces or otherwise facilitates inhibition of bronchoconstriction and/or inflammation in humans and animals.

1/41


**FIGURE 1.**

2/41

Mouse bronchi

FIGURE 2.

3/41

**FIGURE 3.**

4/41

Mouse bronchi






FIGURE 4.

5/41

Guinea-pig trachea


FIGURE 5a.

6/41


FIGURE 5b.


7/41

Guinea-pig Trachea


FIGURE 6.

8/41

FIGURE 7.

**FIGURE 8.**

10/41

FIGURE 9.

11/41

PGs CR CURVE






FIGURE 10.

12/41

PAR-2 RECOVERY FOLLOWING DESENSITIZATION
WITH TRYPSINFIGURE 11a.

**FIGURE 11b.**

14/41




FIGURE 12.

15/41




FIGURE 13.

SUBSTITUTE SHEET (RULE 26) (R0/AU)

16/41

Pig Tracheal Strip




FIGURE 14.

17/41

Rat bronchi




FIGURE 15.

Guinea-pig Taenia Coli





FIGURE 16.

FIGURE 17.

Human Distal Colom




FIGURE 18.

21/41






FIGURE 19.

22/41


**FIGURE 20.**

23/41

**FIGURE 21.**

24/41

A.



B.





FIGURE 22.

25/41

**FIGURE 23.**

Human bronchioles, contracted to 30-40% Fmax with titrated amounts of carbachol





FIGURE 24.

27/41

Human bronchioles, contracted to 30-40% Fmax
with titrated amounts of carbachol



Breaks in traces represent 5 min intervals

FIGURE 25.

28/41







FIGURE 26.


**FIGURE 38.**

30/41

FIGURE 28.

**FIGURE 29.**

32/41

FIGURE 30.

33/41






FIGURE 31.

34/41

**FIGURE 32.**

**FIGURE 33.**

36/41

Human Bronchial Epithelium




FIGURE 34.

37/41

Cytoprotection by epithelium - derived factors




FIGURE 36.

38/41

Effect of inhaled SLIGRL on LPS-induced
neutrophil recruitment in murine lungs




FIGURE 36.

39/41

Monkey Airways




FIGURE 37.

40/41





FIGURE 38.

41/41

Dual compartment model of PAR2 functionality in epithelial cells

**FIGURE 39.**

- 1 -

SEQUENCE LISTING

<110> The University of Melbourne

<120> A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME

<130> EJH/AF

<140>

<141>

<150> PP5922

<151> 1998-09-15

 <150> PP8658

<151> 1999-02-12

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 6

<212> PRT

<213> human cells

<400> 1

Ser Phe Leu Leu, Arg Asn

1

5

<210> 2

<211> 6

<212> PRT

<213> human cells

<400> 2

Ser Leu Ile Gly Arg Leu

1

5

<210> 3

<211> 6

<212> PRT

<213> human cells

<400> 3

- 2 -

Ser Leu Ile Gly Lys Val
1 5

<210> 4
<211> 6
<212> PRT
<213> human cells

<400> 4
Leu Ser Ile Gly Arg Leu
1 5

<210> 5
<211> 7
<212> PRT
<213> human cells

<400> 5
Cys Ser Val Lys Thr Ser Tyr
1 5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 99/00775

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : A61K 38/08; C07K 2/00. 14/705; C12N 15/12																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) FILE WPAT AND CAPLUS KEYWORDS IN ELECTRONIC DATABASE BOX BELOW																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT, CHEMICAL ABSTRACTS. KEYWORDS: PROTEASE ACTIVATED RECEPTOR OR PAR																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
PX	Nature, vol. 398, (11 March 1999), Pages 156-60, (Cocks TM et al.) "A protective role for protease- activated receptors in the airways" See whole document	1-15																				
X	Biochem J, vol. 314 (Pt 3), (15 March 1996) Pages 1009-16, (Bohm SK et al.) "Molecular cloning, expression and potential functions of the human proteinase - activated receptor - 2" See whole document	13, 14 and 15																				
X	Journal of Neurochemistry, vol. 69 (5), (1997), Pages 1890-1896, (Smith - Swintosky VL et al.) "Protease-Activated Receptor-2 (PAR 2) is present in the Rat Hippocampus and is associated with Neurodegeneration". See whole document	10																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>Document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	Document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	Document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 09 November 1999		Date of mailing of the international search report 22 NOV 1999																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No.: (02) 6285 3929		Authorized officer ARATI SARDANA Telephone No.: (02) 6283 2627																				

International application No.
PCT/AU 99/00775

Form PCT/ISA/210 (continuation of second sheet) (July 1998) COPCEW

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 99/00775

Information on patent family members

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
WO	98/18456	EP	948323	US	5892014